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ABSTRACT 
 
Fibroblast growth factors (FGFs) exert diverse biological effects by binding and 
activation of specific fibroblast growth factor receptors (FGFRs). Recent studies on 
the function of FGF2 in MOG35-55-induced experimental autoimmune encephalitis 
(EAE) showed that systemic deletion of FGF2 leads to a more severe disease 
course, increased lymphocyte and macrophage infiltration and decreased 
remyelination. In the present study the in vivo function of the corresponding receptor 
Fgfr1 was characterized using an oligodendrocyte-specific genetic approach. 
Plp/CreERT:Fgfr1fl/fl mice were administered tamoxifen to induce conditional Fgfr1 
deletion in oligodendrocytes (referred to as Fgfr1ind-/-). In MOG35-55-induced EAE the 
Fgfr1ind-/- mice show a delayed onset of disease, less maximum disease severity and 
enhanced recovery. Decreased lymphocyte and macrophage/microglia infiltration, 
and myelin and axon degeneration are found in Fgfr1ind-/- mice. In acute EAE 
downregulation of proinflammatory cytokines such as TNF-α, IL-1β and IL-6, in 
chronic EAE downregulation of the CX3CL1/CX3CR1 pathway is seen in Fgfr1ind-/- 
mice. Furthermore, increased expression of BDNF, TrkB (neurotrophic tyrosine 
kinase receptor, type 2) and decreased expression of Lingo-1 are found in Fgfr1ind-/- 
mice. Fgfr1 ablation in oligodendrocytes showed increased TrkB expression in whole 
lysate of cortex and spinal cord. These data suggest that impaired signalling via 
oligodendroglial Fgfr1 has a beneficial effect on MOG35-55-induced EAE. These 
findings on the oligodendroglial Fgfr1 pathway may offer a new target for developing 
therapy in multiple sclerosis.   
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1 INTRODUCTION 
  
1.1 Multiple sclerosis (MS) 
Multiple sclerosis was first depicted in 1838. The unnamed patient was French, the 
illustrator a Scotsman (Compston et al. 2005). In the six decades that followed, 
French and German physicians provided a coherent clinicopathological account of 
the disease (Compston et al. 2005). By the beginning of the 20th century, a disease 
that earlier had merited individual case reports had become one of the commonest 
reasons for admission to a neurological ward. Now multiple sclerosis is recognized 
throughout the world, with around 2.5 million and one hundred twenty thousand 
people in Germany affected individuals incurring costs in billions of dollars for health 
care. As MS became better recognized in the early part of 20th century, ideas began 
to formulate on its cause and the pathogenesis. Research over the last 50 years has 
illuminated mechanisms of tissue injury, and the therapeutics are which will surely 
culminate in the application of successful strategies both for limiting and repairing the 
damage has begun (Compston et al. 2005).  MS mainly affects women in the age of 
third or fourth decade of life. The usual ratio is two females for one male (2F:M) 
(Goldenberg 2012). It is not always easy to determine the age at which symptoms of 
MS first develop. Some symptoms such as paraesthesia, are nonspecific and often 
so vague as easily to be overlooked. However, there is consensus for peak onset 
around 30 years of age (Compston et al. 2005, Wingerchuk and Carter 2014).  
 
1.1.1 Etiology of MS 
The specific cause (etiology) of MS has not yet been determined (Goldenberg 2012), 
several theories are plausible either immunologic, genetic, microbial or environmental 
factors. Although no definite cause of MS has yet been identified, substantial 
amounts of research point to a dual multifactorial influence of both genetics and 
environmental elements contributing to the development of the disease (Hoglund and 
Maghazachi 2014). Family studies support a genetic association, they also show that 
genetics alone are not enough to develop MS, as shown by homozygous twins not 
both acquiring disease. Studies have shown risk association during months of birth 
as spring births have higher risk of MS than autumn births and Vitamin D3 deficiency 
increases the risk of MS (Hoglund and Maghazachi 2014). Another risk factor with 
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strong association to MS is Epstein Barr Virus (EBV) infection. Many other factors 
have shown association with increased MS risk but are in need of further research to 
be conclusive. These include cigarette smoking, a diet rich in saturated but low in 
polyunsaturated fats, sex hormones, and socioeconomic status, among others. 
Viruses other than EBV have also been implicated in the etiology of MS (Hoglund 
and Maghazachi 2014). 
 
1.1.2 MS symptoms 
The clinical course of MS is as unpredictable as the symptoms that may occur but 
some patterns can usefully be defined (Compston et al. 2005). The most commonly 
affected sites to produce symptoms are the optic nerves, the cerebrum and the spinal 
cord. The major symptoms are shown in Figure 1. These will be affected in most 
patients at some stage in the illness. The spinal cord is predominantly involved in 
most patients with progressive MS, whether this occurs after a period of relapsing 
disease or from onset. Selective involvement of the optic nerves, cerebrum and 
brainstem may also progressive blindness, dementia, or ataxia (Compston et al. 
2005).  
 
Figure 1 Symptoms of Multiple sclerosis. Figure shows the major symptoms of 
MS in percentage. Walking difficulty, vision problems and numbness are widely 
observed symptoms. (source: multiplesclerosis.net) 
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MS shows a number of unpredictable symptoms including pain, tingling or burning 
sensations throughout the body, vision problems, mobility difficulties, muscle spasms 
or stiffness, slurred speech, impaired memory and cognitive function. The course of 
multiple sclerosis can be described in terms of relapses, remissions and chronic 
progression either from onset or after a period of remissions. Two major outcome 
measures usefully describe the clinical course and prognosis: the qualitative 
description, an expression of the interplay between relapses and progression; and 
the quantitative description, which refers to the accumulation of neurological deficits 
and is characterized as disability, impairment or loss of social functions. 
 
1.1.3 Subtypes of MS  
There are several MS subtypes by the terms of clinical course and disease 
pathology. (i) relapsing-remitting MS (RR-MS) clearly defined relapses with full 
recovery or with sequlae and sidual deficits upon recovery; periods between disease 
replaces characterized by a lack of disease progression (approximately 85% patients 
have RR-MS) (Rangachari and Kuchroo 2013); (ii) secondary progressive MS (SP-
MS), which is characterized by initial relapsing-remitting disease course followed by 
progression with or without occasional relapses, minor remissions, and plateaus; (iii) 
primary progressive MS (PP-MS), defined disease progression from onset with 
occasional plateaus and temporary minor improvements allowed (affects 
approximately 15% of people with MS); (iv) progressive-relapsing MS (PR-MS) is 
rare variant and shows progressive disease from onset, with clear acute relapses, 
with or without full recovery; periods between relapses characterized by continuing 
progression (Compston et al. 2005, Constantinescu et al. 2011).  
 
1.1.4 MS pathology 
Multiple sclerosis is an autoimmune chronic neuroinflammatory demyelinating 
disease of the central nervous system (Goldenberg 2012). Inflammation, 
demyelination and axonal loss are major pathological features of MS (Constantinescu 
et al. 2011). Multiple sclerosis has acute and chronic lesions. Active demyelination 
and inflammation with various immune cells are pathology of acute lesion, whereas in 
chronic lesions, significant loss of myelin with less inflammatory infiltrates and gliosis 
(Constantinescu et al. 2011, Milo and Miller 2014).     
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Figure 2  Pathology of MS. A) One of the axons ends in a large swelling (arrow) or 
axonal retraction bulb (arrow). B and C) schematic of axonal response during and 
following transection (Dutta and Trapp 2011). D) LFB staining reveal areas of 
myelination in the subcortical white matter. The green arrows indicate three areas 
from which the myelin stain is absent, representing three foci or plaques of chronic 
demyelination (Robin JM Franklin 2002). E) neurofilament stain of the lateral 
corticospinal tract of a patient with MS demonstrates extensive axonal loss compared 
to control tissue (Bø et al. 2013). MRI in a patient with multiple sclerosis 
demonstrates numerous white matter plaques in a callosal and pericallosal white 
matter distribution. 
 
MS lesions can arise anywhere in the CNS. However, they show a predilection for 
the optic nerve, spinal cord, brain stem, and periventricular areas. Furthermore, brain 
tissue immediately adjacent to the subarachnoid space, i.e. subpial gray matter, is 
especially vulnerable to demyelination. Mild meningeal inflammation consisting of T 
and B lymphocytes, plasma cells and macrophages is common pathology of MS 
(Stadelmann et al. 2011). Reactive astrocytes may still be present at the lesion 
border; more prominent, however, a dense, fibrous gliosis. In contrast to these 
seemingly inert lesions, scattered macrophages digesting myelin products may be 
present at the lesion edge, mostly accompanied by scattered perivascular and 
parenchymal T cells, indicating ongoing myelin destruction. Accordingly, signs of 
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axonal damage are routinely found at the edge of slowly expanding lesions. In 
general, T cell lymphocytic infiltration decreases over time and is markedly reduced 
in late stage MS (Stadelmann et al.  2011). Early MS lesions mostly appear pale, but 
not completely devoid of myelin. Oligodendroglial cells are present in the lesions, 
often displaying an activated phenotype with signs of early remyelination. 
Early MS lesions are more likely to be encountered in patients who have been 
biopsied for reasons of differential diagnosis, but may also be found at autopsy, 
especially in patients dying early in the disease course. The most studied lesions are 
“early active demyelinating” MS lesions where macrophages filled with minor, i.e. low 
abundance myelin proteins, such as myelin oligodendrocyte glycoprotein (MOG), 
cyclic nucleotide phosphodiesterase (CNPase) and myelin-associated glycoprotein 
(MAG) cover most or part of the lesion area (Stadelmann et al. 2011). Although 
demyelination as hallmark of MS is largely restricted to focal lesions, other aspects of 
pathology are less confined. Perivascular and also scattered parenchymal T cell 
infiltration and microglia activation are widespread in many MS patients, even in the 
chronic disease phase. 
 
1.1.5 MS diagnosis 
The diagnosis of MS is primarily with clinical symptoms and white matter lesions 
signs. There is no single laboratory test for MS diagnosis. Analysis of increased 
oligoclonal bands (OCBs) from the CSF is one step in MS diagnosis. MRI is the most 
sensitive test to detect and demonstrate MS lesions. It supports the diagnosis, 
estimates the lesion load and disease activity, measures brain atrophy and axonal 
loss (Milo and Miller 2014). Revised versions (2010) of McDonald criteria facilitate the 
diagnosis of MS (Table 1; Milo and Miller 2014). The diagnosis of MS is based on the 
evaluation of lesions in CNS (Figure 2) and alternative diagnosis.  
PPMS May Be Diagnosed in subjects with: (Revisions to MS Diagnosis, Polman et al. 
2010) 
1. One year of disease progression (retrospectively or prospectively determined). 
2. Plus 2 of the 3 following criteriaa: 
A. Evidence for DIS in the brain based on ≥ 1 T2b lesions in at least 1 area   
     characteristic for MS (periventricular, juxtacortical, or infratentorial). 
B. Evidence for DIS in the spinal cord based on ≥ 2 T2b lesions in the cord. 
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C. Positive CSF (isoelectric focusing evidence of oligoclonal bands and/or  
    elevated IgG index). 
a If a subject has a brainstem or spinal cord syndrome, all symptomatic lesions are  
  excluded from the criteria. 
b Gadolinium enhancement of lesions is not required. 
  DIS = lesion dissemination in space; IgG = immunoglobulin G. 
Table 1 The 2010 McDonald criteria for diagnosis of MS. (Revisions to MS 
diagnosis, Polman et al. 2010) 
Clinical presentation Additional data needed for MS diagnosis 
≥ 2 attacks; objective 
clinical evidence of ≥ 2 
lesions or objective clinical 
evidence of 1 lesion with 
reasonable historical 
evidence of a prior attack 
None 
≥ 2 attacks; objective 
clinical evidence of 1 lesion 
Dissemination in space, demonstrated by: ≥ 1 T2 lesion in 
at least 2 of 4 MS-typical regions of the CNS 
(periventricular, juxtacortical, infratentorial, or spinal cord); 
or Await a further clinical attack implicating a different CNS 
site. 
1 attack; objective clinical 
evidence of ≥ 2 lesions 
Dissemination in time, demonstrated by: Simultaneous 
presence of asymptomatic gadolinium-enhancing and 
nonenhancing lesions at any time; or A new T2 and/or 
gadolinium-enhancing lesion(s) on follow-up MRI, 
irrespective of its timing with reference to a baseline scan; 
or Await a second clinical attack. 
1 attack; objective clinical 
evidence of 1 lesion 
(clinically isolated 
syndrome) 
Dissemination in space and time, demonstrated by: For 
DIS: ≥ 1 T2 lesion in at least 2 of 4 MS-typical regions of 
the CNS (periventricular, juxtacortical, infratentorial, or 
spinal cord); or Await a second clinical attack implicating a 
different CNS site; and For DIT: Simultaneous presence of 
asymptomatic gadolinium-enhancing and nonenhancing 
lesions at any time; or A new T2 and/or gadolinium-
enhancing lesion(s) on follow-up MRI, irrespective of its 
timing with reference to a baseline scan; or Await a second 
clinical attack. 
Insidious neurological 
progression suggestive of 
MS (PPMS) 
1 year of disease progression (retrospectively or  
prospectively determined) plus 2 of 3 of the following 
criteria:  
1. Evidence for DIS in the brain based on ≥ 1 T2 lesions in  
     the MS-characteristic (periventricular, juxtacortical, or  
     infratentorial) regions 
2. Evidence for DIS in the spinal cord based on ≥ 2 T2  
     lesions in the cord 
3. Positive CSF (isoelectric focusing evidence of oligoclonal  
    bands and/or elevated IgG index) 
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1.1.6 MS treatment 
There is no cure for MS, whereas disease modifying therapy (DMT) can reduce 
disease activity and progression of the disease (Goldenberg 2012). The first line of 
treatment was represented by β-Interferons (INF) and glatiramate acetate (GA) (Milo 
and Miller 2014). Currently, there are nine approved MS DMTs (interferon beta 1a/b, 
GA, natalizumab, fingolimode, alemtuzumab, dimethyl fumarate, mitoxantrone, 
teriflunomide) (Brück et al. 2012) with varying degrees of efficacy for reducing 
relapse risk and preserving neurological function, but their long-term benefits remain 
unclear. Moreover, available DMTs differ with respect to the route and frequency of 
administration, tolerability and likelihood of treatment adherence, common adverse 
effects, risk of major toxicity, and pregnancy-related risks (Wingerchuk and Carter 
2014). 
Five interferon beta preparations and glatiramer acetate (GA) are approved for 
relapsing MS (Milo and Miller 2014). Their mechanisms of action are not fully 
understood, but interferon beta reduces BBB disruption and modulates T-cell, B-cell, 
and cytokine functions, whereas GA regulates the shift of Th1 to Th2 cells. 
Mitoxantrone is a general immunosuppressive drug approved for rapidly worsening 
relapsing MS and is the only agent approved to treat secondary progressive MS. 
Natalizumab is a humanized monoclonal antibody that selectively targets the α4 
subunit of the cell adhesion molecule “very late antigen 4” expressed on the surface 
of lymphocytes and monocytes (Brück et al. 2012).  
Three oral DMTs are approved for relapsing MS: fingolimod, teriflunomide, and 
dimethyl fumarate/BG-12. Fingolimod is a once-daily oral medication approved for 
relapsing MS. It is a sphingosine-1-phosphate (S1P) agonist, binding to 4 of the 5 
S1P receptor subtypes, but acts as a functional antagonist (Goldenberg 2012). 
Teriflunomide, a once-daily oral DMT, is the active metabolite of the rheumatoid 
arthritis drug leflunomide. It exerts immunological effects by inhibiting dihydroorotate 
dehydrogenase, an enzyme required for de novo pyrimidine synthesis in proliferating 
(but not resting) cells. Dimethyl fumarate (DMF) is a newly approved twice-daily oral 
DMT for relapsing MS. On ingestion, it is hydrolyzed to monomethyl fumarate, which 
is eliminated through respiration and has little hepatic or renal excretion. The 
mechanism of DMF action has not been completely elucidated, but it is known to 
activate the nuclear-related factor 2 transcriptional pathway, which reduces oxidative 
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cell stress, as well as to modulate nuclear factor kB, which could have anti-
inflammatory effects (Brück et al. 2012). 
Emerging therapies include humanized monoclonal antibodies such as alemtuzumab 
(against CD52), Ocrelizumab (against CD20), Laquinimod (unknown mechanism) 
and daclizumab (against α subunit (CD25) on T cells) are in clinical trials for MS 
treatment (Wingerchuk and Carter 2014). 
 
1.2 Experimental autoimmune encephalomyelitis (EAE) 
Three different types of animal models are currently established for the exploration of 
pathologic patterns of demyelinating diseases, a) Theiler´s murine encephalomyelitis 
virus (TMEV) model, b) cuprizone induced toxic model and c) EAE, which is the most 
common animal model for MS (Bittner et al. 2014). Experimental autoimmune 
encephalomyelitis is a common term referring to different models of CNS 
autoimmunity in vertebrate animals. EAE is a well-established animal model for MS 
which mimics pathology of human MS. Till end of 2014 around 7500 research articles 
were published with EAE models (Pubmed search EAE as key word). 
In 1920s, Koritschoner and Schewinburg induced spinal cord inflammation in rabbits 
by inoculation with human spinal cord that is the origin of EAE. In 1930s, researchers 
attempted encephalitic complications associated with rabies vaccination by repetitive 
immunization of rhesus monkeys with CNS tissue (Gold et al. 2006). Since then EAE 
is classically induced by immunization of many different species, including mice, rat, 
rabbit, guinea pig, monkeys non-human primates with encephalitogenic antigens 
derived from CNS myelin related gene proteins mainly myelin oligodendrocyte 
glycoprotein (MOG), proteolipid protein (PLP) and myelin basic protein (MBP) 
(Rangachari and Kuchroo 2013, Milo and Miller 2014). 
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Figure 3 Schematic diagram of MOG induced EAE mechanism. A) Following 
induction of autoimmune conditions in mice using MOG35-55 immunization, 
differentiated T- cells secrete proinflammatory cytokines such as TNF-α, IL-17, IL-6, 
IL-23, NO, TGFβ and activated macrophages destroy myelin and damage 
oligodendrocytes (Cytokine technical resources, R and D Systems, Germany). B) 
Clinical course of EAE in mice model (Hooks Laboratory, EAE protocol). C) 
Experimental procedure of MOG EAE induction and expected EAE score.  
 
         Introduction    
10 
 
A major difference between MS and EAE is that external immunization of myelin 
antigen is required in EAE. In EAE the inducible agent is well known whereas in MS 
the causative agent is not known.  There are different models of EAE using in MS 
researchers in which each model shows different and distinct aspects of MS 
pathology. http://www.jove.com/video/51275 provides the protocol for MOG EAE 
induction video (Bittner et al. 2014). Immunization of animals with myelin peptides 
induces the auto reactive inflammatory immune cells (T and B cells) and combination 
of complete Freunds adjuvant and pertussis toxin facilitate the blood brain barrier to 
allow the myelin activated immune cells into the CNS. Inflammatory immune cell 
infiltration occurs in CNS upon the entry of activated immune cells into the CNS 
(Figure 3). EAE disease onset starts 9-12 days post immunization and shows 
different clinical and pathological symptoms. The EAE clinical symptoms can be 
measured by the scale range of 1-5 (detailed in method section 3.2.1.7). MOG is 
unique myelin auto antigens that induce encephalitogenic T-cell response and also a 
demyelinating autoantibody response. Demyelinating anti-MOG antibodies augment 
disease severity and initiate extensive demyelination in T-cell-mediated brain 
inflammation in mouse, rat and primate EAE models (Gold et al. 2006). 
In MOG-induced EAE, the lesions are in general characterized by massive global 
tissue injury (including axonal and neuronal damage) with very little primary 
demyelination and tissue damage is accomplished by T cells and activated 
macrophages (Gold et al. 2006). The limitation of EAE is a) sometimes, low disease 
incidence or weak symptoms might be an experimental challenge, b) disease severity 
can be varied with different amounts of peptide/mouse, c) age, gender, season of the 
year and environmental conditions within the animal facility are important factors that 
influence EAE susceptibility (Bittner et al. 2014). 
Another method of EAE induction is adoptive transfer of myelin antigen activated 
myelin-specific T cells into the animals induces the disease in recipient animals. In 
vitro, myelin-antigen-specific T cells cultured in different conditions and adoptive 
transfer to the animals to investigate the effect of particular compounds (Rangachari 
and Kuchroo 2013, Milo and Miller 2014). MOG35-55 peptides are the widely used 
antigen to induce EAE in mice and rats, PLP139-151 also used to induce EAE. Mice 
immunized with PLP139-151 developed splenic lymphocyte responses to PLP178-191 that 
could induce EAE upon adoptive transfer. Further, MBP84-104 peptide showed delayed 
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EAE responses (Rangachari and Kuchroo 2013). MOG37-46 peptides also induce 
specific CD8+ T cell response in B6 mice. Other method of EAE induction is 
spontaneous induction of EAE on SJL/J mice. Wekerle et al. have developed 
spontaneous EAE by generating a MOG92-106-specific TcR transgenic in SJL/J 
background (Rangachari and Kuchroo 2013). MOG35-55 peptide induced EAE is the 
common and chronic form of EAE that did not show remittance. The dose of MOG35-
55 peptide influence the disease course of EAE, the high dose of MOG35-55 peptide 
(300 µg) induces chronic non-remitting EAE in C57/Bl6 mice, whereas lower doses of 
peptide (50 µg) shows relapsing-remitting EAE (Rangachari and Kuchroo 2013). 
 
1.3 Oligodendrocytes in MS and EAE 
The central nervous system (CNS) is responsible for integrating information from and 
to the peripheral system and responds accordingly. CNS consists of two major 
anatomical parts such as spinal cord and brain. The nervous system is consisting of 
nerve cells and unique cells known as glial cells. These glial cells are non-neuronal 
cells that primarily support the protection and functions of the neurons. 
Oligodendrocytes are glial cells present in the CNS. In the CNS, oligodendrocytes 
produce myelin by the elaboration of the oligodendrocyte plasma membrane which 
wrap around in to the axons. This makes the myelin sheaths compact and 
multilamellar sheaths.  Myelin is a lipoprotein ensheathment of the axons with the 
thickness of 1 µm and forming nodes of Ranvier. Myelin sheath protects the axons 
from the injury and increase the rate and efficacy of nerve conduction. A single 
oligodendrocyte can form myelin sheaths to more than one axon (up to 50) and 
renew its myelin sheaths three times within 24 h (Patel and Balabanov 2012). 
Impaired myelin formation or myelin sheath damage is the major pathology in MS 
and its animal model EAE (Bansal 2002). Demyelination process compromises the 
salutatory property of the axonal action potential and blocks the axonal conduction.  
Besides protecting axons by the insulating myelin sheath, oligodendrocytes produce 
many neurotropic factors (BDNF, GDNF, FGF) that are well known to promote the 
survival of neurons as well as advancing oligodendrocyte differentiation and 
myelination, especially during CNS myelin lesion and repair. Neuron-astrocyte-
oligodendrocyte interaction loop involving astrocyte-produced trophic factors has also 
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been suggested for oligodendrocytes to achieve CNS myelination and protection. 
Oligodendrocytes play major roles in supporting axonal metabolism and 
oligodendrocyte impairment contributes to the onset and/or progression of 
neurodegeneration (Bankston et al. 2013). 
Inflammatory demyelination process can be altering by the regulatory signals 
produced by the oligodendrocytes (Patel and Balabanov 2012). Invading 
macrophages (monocytes) and microglia remove the myelin from the axons. The 
specific mechanisms of oligodendrocyte injury involve immune cells, mainly T and B 
cells. Activated T cells produce inflammatory cytokines (IFN-γ and TNF-α), which 
affect oligodendrocytes and myelin sheaths. B cells in the lesion area produce 
antibodies against oligodendrocytes and myelin. Myelin oligodendrocyte glycoprotein 
(MOG) and galactocerebroside are the major targets of antibody-mediated 
cytotoxicity (Patel and Balabanov 2012).  
Myelin repair process by oligodendrocytes largely fails, because the inability of 
oligodendrocyte progenitor cells (OPC) to proliferative or differentiate into myelin-
producing cells. OPC are very sensitive to inflammatory cytokines compared to 
mature oligodendrocytes. Newly formed myelin is thinner and has shorter internodes 
than normal myelin. Demyelination and oligodendrocyte injury in MS and EAE are 
complex immune processes. Oligodendrocyte injury is the first stage of disease 
process in MS and EAE. So the protection of oligodendrocytes against injury resulted 
in the protection from MS and EAE. Till to date, there is no oligodendrocyte-based 
treatment for MS, however all the available disease-modifying agents providing little 
direct protection to oligodendrocytes and myelin sheaths (Patel and Balabanov 
2012).  
 
1.4 Fibroblast growth factors (FGFs) 
Genetic location analysis showed that the human and mouse FGF family consist of 
seven FGF subfamilies, all members share homology and similar binding specificity 
to their respective receptors (Itoh and Ornitz 2008). FGF family members are 
classical signalling molecules which are extracellular secreted proteins mostly and 
they bind to the heparan sulfate proteoglycans (HSPGs). FGFs act in an autocrine or 
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paracrine fashion by interacting with high affinity and different degrees of specificity, 
with tyrosine kinase receptors (FGF receptors) present at the cell surface.  
The 23 human and mouse FGF ligands can be subdivided in to i) canonical (cFGFs), 
ii) intracellular (iFGFs), and iii) hormone like (hFGFs) subfamilies (Itoh and Ornitz, 
2008). FGF15/19, FGF21, and FGF23 have reduced heparan binding affinity and act 
as a long distance as endocrine factor to regulate metabolism and these FGFs called 
‘‘hormone-like’’ FGFs. Another set of FGFs (FGF11, 12, 13 and 14) are intracellular 
FGFs which are secreted by the cells intracellularly and they do not activate FGF 
receptors (Figure 4). These FGFs localized to the nucleus and interact with 
intracellular domains of voltage gated sodium channels (Itoh and Ornitz 2008). 
Fibroblast growth factors regulate a wide range of cellular functions, regulating 
proliferation, differentiation, survival, migration and differentiation of different cell 
types. FGF family consists of 23 members, out of this FGF 11, FGF 12, FGF 13 and 
FGF 14 was not function as FGF ligand, and is described as FGF homologous 
factors. FGF15 is not expressed in human. 
 
 
Figure 4 The FGF signalling system (Goetz and Mohammadi 2013) A) The 18 
mammalian fibroblast growth factor (FGF) ligands are listed, grouped by subfamily 
and mode of action. The ligand which each subfamily is named after is boxed in 
orange. The crystal structures of FGF2, a prototypical paracrine FGF and FGF19, an 
endocrine FGF 14 are shown. B) The crystal structure of the ternary complex of 
FGF2, FGFR1c and heparan sulphate 4 as well as a schematic of the paracrine FGF 
signal transduction unit based on this structure are shown. 
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FGF-2 is considered to be one of the most controversial in terms of oligodendrocyte 
lineage and myelin repair. Administration of neutralizing antibodies against 
endogenous FGF2 reduces the rate of neural proliferation and development. In mice 
models FGF2 reduces inflammation by decreasing inflammatory cells such as 
macrophages, microglia, CD8 T cells (Ruffini et al. 2001, Rottlaender et al. 2011) and 
limited the CD44-mediated leukocyte migration (Jones et al. 2000). FGF activity is 
mediated through FGFR1, which is expressed in both embryonic and adult OPCs. 
FGF-2 affects the oligodendroglial cells and it arrests OPC differentiation in vitro and 
pathological conditions (Clemente et al. 2013). 
 
1.5 Fibroblast growth factor receptors (FGFR) 
There are four main FGF receptors (FGFR1 to 4) regulating FGF signals. Structurally 
FGF receptors have an extracellular domain, transmembrane domain and 
intracellular domain. The extracellular domain composed of three Immunoglobulin-
like domains (IgGI-IgGIII), which facilitate FGF ligand to the receptor. The 
extracellular domain has an acid box (AB) domain and a heparin sulfate 
proteoglycans binding regions, which are regulating the receptor to the extracellular 
molecules, particularly cell adhesion molecules (CAMs). Extracellular and 
intracellular domains are joined with transmembrane domain. Following the 
transmembrane domain, the intracellular domain present inside the cell body, which 
has the tyrosine kinase domain (KI, KII), which contains the catalytic activity of the 
receptor. Transmembrane domain has the autophosphorylation sites which interact 
with intracellular substrates. The specificity and the tissue-specific alternative splice 
variant were determined by the half of the IgGIII which generate two isoforms, IIIb 
and IIIc which have very different ligand binding specificity (Zhang et al. 2006). The 
FGFR1 splice forms IIIa, IIIb and IIIc were differentiated by the third part of the third 
Ig-like domain (Figure 5).  
FGFR1 is composed of an extracellular ligand-binding domain, a unique 
transmembrane domain, and a catalytic (tyrosine kinase) cytosolic domain. The 
extracellular region (with the N-terminus) contains a signal peptide (amino acids (aa) 
1-21), 3 immunoglobulin-like loops (aa: 25-119, 158-246, and 255-357 according to 
Swiss-Prot), with an acidic box (seven glutamic acids in 127-133) between IgI and 
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IgII, a CHD (Cell adhesion molecule (CAM) homology domain) in 151-170, and an 
heparin-binding domain in the beginning of the IgII (aa 166-177); this extracellular 
region is followed by a transmembrane domain (aa 377-397) and an intracellular 
domain composed of a juxtamembrane domain, which serves as a binding site for 
phosphotyrosine binding (PTB) domains of proteins such as FRS2, and a tyrosine 
kinase domain (aa 478-767) (two kinase domains interrupted by a short kinase insert 
of 14 amino acids), and a C-terminal tail. A part of the C-terminal tail of FGFR1 
containing 28 amino acids binds the SH2 domain of PLCG (PLC gamma) (Figure 5 
and 6).  
 
Figure 5  The FGF receptor 1 structure. IgG domain and cytoplasmic tyrosine 
kinase domain is attached by transmembrane domain (top box). Soluble form of 
FGFR1 showed (A and B). Membrane attached complete form of Fgfr1 showed in C, 
D, and E. Adapted from Johnson and Williams 1993, and Splice Center data.  
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Phosphorylation of tyrosine 766 is the interactive item with PLC gamma (Itoh et al. 
1990, Johnson and Williams, 1993). The five tyrosine autophosphorylation sites in 
the catalytic core of FGFR1 are phosphorylated by a precisely controlled and ordered 
reaction. The rate of catalysis of two substrates is enhanced by 50- and 500-fold after 
autophosphorylation of Y653 and Y654, respectively, in the activation loop of FGFR1 
(Furdui et al. 2006). 
 
1.6 Fibroblast growth factor/FGF receptor interaction 
FGF/FGF receptor interaction downstream regulates multiple signalling pathways 
involving various cellular functions such as proliferation, migration and differentiation 
(Figure 7). Following ligand binding and receptor dimerization, the kinase domains 
transphosphorylate each other, leading to the docking of adaptor proteins and the 
activation of four key downstream pathways: RAS-RAF-MAPK, PI3K-AKT, signal 
transducer and activator of transcription (STAT) and phospholipase Cγ (PLCγ) 
(Turner and Grose 2010).  
 
Figure 6 Structure and family members of FGF ligands and the respective FGF 
receptor subtype’s specificity (Guillemot and Zimmer 2011). FGFR numbers 
depicted in bold letters indicate high-affinity binding to the ligand in the same line; in 
plain letters they indicate intermediate affinity binding, and in italic they indicate lower 
affinity binding. 
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Figure 7 FGF signalling pathways (Goetz and Mohammadi, Nat Rev Mol Cell Biol, 
2013). Binding of fibroblast growth factor (FGF) to the FGF receptor (FGFR) induces 
FGFR dimerization, which juxtaposes the intracellular Tyrosine kinase domains of the 
receptors so that kinase activation by transphosphorylation can occur. The outcome 
of FGF/FGFR1 pathway is primarily cell proliferation (a) but can also lead to cell 
differentiation (b), cell migration (c) or another cellular response.  
 
 
The major pathway, which is mediated by FGF/FGFR signalling is the proliferative 
pathway MAPK/ERK signalling cascade which resulted in the activation of various 
transcriptional factors such as Ets protein, AP1, GATA proteins, and CREB. The 
second pathway, the PLCg/Ca2+ pathway is activated by FGF/FGFR interaction, 
which stimulate neurite outgrowth by FGF2 (Doherty and Walsh, 1996). The other 
pathway, which is mediated by FGF/FGFR signalling is PI3 kinase/AKT pathway, 
which regulate cell proliferation and survival. FGF/FGFR signalling involve in multiple 
developmental processes in embryogenesis such as implantation, gastrulation, 
somitogenesis, body plan formation, morphogenesis and organogenesis (Belov and 
Mohammadi 2013). 
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1.7 FGFR1 in oligodendrocyte lineage 
 
FGF receptor expression in oligodendrocyte lineage is distinct in different stage of 
oligodendrocyte lineage. FGFR1 is expressed in all stages of oligodendrocyte 
lineage cells. FGFR2 is expressed in mature oligodendrocytes. FGFR3 is expressed 
in early and late progenitors. FGFR4 is not expressed by any stage of 
oligodendrocyte lineage cells. FGF2 up-regulates FGFR1 in early and late 
progenitors whereas downregulates FGFR2 in mature oligodendrocytes (dotted line 
the Figure 8). FGFR1 in early progenitors stimulate proliferation and migration. 
FGFR1 mRNA has been detected in preprogenitors by PCR (Bansal 2003). Exposure 
of FGF-2 to terminally differentiating oligodendrocytes resulted in i) down regulation 
of myelin specific gene expression such as myelin basic protein, proteolipid protein, 
ii) increases in the length of cellular process iii) cell cycle re-entry without finishing 
mitosis, iv) importantly altering the expression patterns of low and high affinity FGF 
receptors (Bansal and Pfeiffer 1997). FGFR1 expression increases in the 
oligodendrocyte lineage and the predominant is FGF receptor 1 transcript variant 
alpha (FGFR-1α). Expression of FGFR1 level in astrocytes is different compared to 
oligodendrocytes lineages, as astrocytes express more FGF receptor-1β (Bansal et 
al. 1996).  
 
 
 
Figure 8 FGFR expression pattern in developing oligodendrocyte lineage with 
stage specific cell marker (Pfeiffer et al. 1993, Bansal 2002). Inhibition of early or 
late progenitors by FGF2 is shown. 
         Introduction    
19 
 
1.8 FGF/FGFR1 in demyelinating disease MS and its animal model EAE 
 
In vitro and in vivo data suggest that FGF2 plays a role in demyelinating pathologies. 
The most common demyelinating disease is multiple sclerosis (MS). In postmortem 
brain tissue from patients with multiple sclerosis, FGF2 is expressed in active lesions 
and in the periplaque of chronic lesions (Clemente et al. 2011). Furthermore, high 
levels of FGF2 protein expression are found during relapse in serum (Harirchian et al. 
2012) and cerebrospinal fluid (CSF) (Sarchielli et al. 2008). In vitro activation of the 
FGF2/FGFR1 pathway results in downregulation of myelin proteins (Fortin et al. 
2005). In MOG35-55-induced experimental autoimmune encephalomyelitis (EAE), the 
most widely used animal model of multiple sclerosis, FGF2 ablation leads to a more 
severe disease course, increased lymphocyte and macrophage infiltration and 
decreased remyelination (Rottlaender et al. 2011). This finding is supported by a 
FGF2 gene therapy study in EAE resulting in less disease severity, reduced 
lymphocyte and macrophage infiltration and an increased number of myelin-forming 
oligodendrocytes (Ruffini et al. 2001). These data support an important role of FGF2 
in multiple sclerosis and EAE.  
The function of the corresponding receptor FGFR1 in multiple sclerosis and EAE is 
not well- defined. FGFR1 is present on oligodendrocytes, astrocytes and neurons in 
humans (Galvez-Contreras et al. 2012) and rodents (Reuss et al. 2003). However, it 
is also expressed on lymphocytes, macrophages and microglia in rats (Liu et al. 
1998). In patients with multiple sclerosis FGFR1 is upregulated in oligodendrocyte 
precursor cells in active lesions, chronic-active and chronic-inactive lesions 
(Clemente et al. 2011). In rats FGFR1 is expressed on macrophages/activated 
microglia in the acute phase of EAE (Liu et al. 1998). 
Butt and Dinsdale (2005) showed the raised FGF2 induces disruption of mature 
oligodendrocytes and severe loss of myelin. Moreover, they showed the aberrant 
accumulation of immature oligodendrocytes in the pre myelinating phenotype in 
FGF2 treatment. And they demonstrated that increased FGF2 induces demyelination 
in the adult rat CNS (Butt and Dinsdale, 2005). FGF treated mice in EAE model 
showed abrogate demyelination (Ruffini et al. 2001). In cuprizone mediated non-
immune demyelination-remyelination model, FGF2 expression level was increased 
during both demyelination and remyelination (Gudi et al. 2011). Depending on the 
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oligodendrocyte developmental stage and level of concentration, FGF2 has both 
positive and negative effects. 
 
1.9 FGF/FGFR signalling in disease 
FGF receptor signalling mediating major cancer types in human beings. FGFR1 
amplification is involved in breast, lung, squamous cell carcinoma, esophageal, 
ovarian and osteosarcoma (Dienstmann et al. 2014). Table 2 shows the involvement 
of FGFR1 in various cancer types in human beings. FGF signalling involved in many 
metabolic processes such as phosphate and vitamin D homeostasis, cholesterol and 
bile acid homeostasis, and glucose/lipid metabolism (Belov and Mohammadi 2013). 
Endocrine FGFs also involved in metabolic disorders such as chronic kidney disease, 
obesity and insulin resistance (Belov and Mohammadi 2013). Whereas, FGF/FGFR 
pathway implicated in the protection of neurons against neurotoxins and FGF have 
been shown to protect neurons by down-regulating the expression of the chemokine 
receptor CXCR4, activating cell-survival signalling and inhibiting the internalization of 
HIV-1 coded proteins (Sanders et al. 2000, Bachis et al. 2003). At least three genetic 
disorders can be attributed to mutations in FGFR1: Kallman´s syndrome, 
ostroglophonic dysplasia and Pfeiffer´s syndrome. Pathological Fgfr1 signalling also 
occurs in various malignancies (Beenken and Mohammadi 2009) (Table 2).  
Table 2 Genomic deregulation of FGFR in tumors (Dienstmann et al. 2014). 
FGFR1 amplification and mutations involved in various cancer types in human 
beings. 
Aberration Tumor 
FGFR1 Amplification Breast (hormone receptor positive) 
Lung (squamous cell carcinoma) 
Lung (small cell) 
Head and neck (squamous cell carcinoma) 
Esophageal (squamous cell carcinoma) 
Ovarian 
Osteosarcoma 
FGFR2 Amplification  
 
Mutation 
Breast (triple-negative) 
Gastric 
Endometrial 
FGFR3 Mutation Bladder (muscle-invasive) 
Glioblastoma 
FGFR4 Amplification 
Mutation 
Colorectal 
Rhabdomyosarcoma 
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1.10 FGFR inhibitors in clinical trails 
FGFR are receptor tyrosine kinases (RTKs) that regulate proliferation, differentiation 
and signalling processes in various cell types. Recently there are tyrosine kinase 
inhibitors (TKI) in cancer and autoimmune disease clinical trials (Mirschafiey et al. 
2014). TKIs are a class of chemotherapy medications that block, or inhibit the 
enzyme tyrosine kinase. Imatinib, sorafenib, dasatinib, sunitinib, nilotinib, gefitinib, 
erlotinib, bosutinib, lapatinib, pazopanib and regorafenib are the TKI in clinical 
studies (Mirschafiey et al. 2014). All these inhibitors are ATP inhibitors at the catalytic 
binding site of tyrosine kinase and they differ from each other in the spectrum of 
targeted kinases, pharmacokinetics and substance specific adverse side effects 
(Hartmann et al. 2009). Imatinib, sunitinib, lestaurtinib (CEP-701), sorafenib 
(nexavar) and masitnib (AB1010) shows effects in MS and EAE study (Mirschafiey et 
al. 2014).  
 
 
Table 3 FGFR inhibitors in clinical development. (Daniele et al. 2012, Dienstmann 
et al. 2014). 
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There are various knockdown studies and selective pharmacological inhibition in 
preclinical models conclude that FGFRs as attractive targets for the therapeutic 
intervention in cancer studies (Dienstmann et al. 2014) (Table 3). Most FGFR 
inhibitors currently in development are small molecule kinase inhibitors of the ATP-
binding domain.  Selective FGFR tyrosine kinase inhibitors, monoclonal antibody that 
bind to the extracellular domain of FGFRs and block FGF ligand, thereby blocking 
FGFR dimerization and downstream activation are also in clinical testing. 
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2 AIMS 
 
Based on the recent findings on the function of FGF2 in EAE it was hypothesized that 
deletion of oligodendroglial Fgfr1 would result in a more severe disease course, 
increased inflammation and neurodegeneration. Aim of the study was to characterize 
and evaluate the role of oligodendrocyte specific Fgfr1 in experimental autoimmune 
encephalomyelitis, an animal model of multiple sclerosis.   
 
The objectives of this study are 
1. To evaluate the role of oligodendrocyte specific Fgfr1 in EAE (Inflammation, 
demyelination, axons, cytokines, chemokines and growth factor expression). 
 
2. To characterize the role of oligodendrocyte specific Fgfr1 signalling pathway in 
C57Bl/6J mice. 
 
3. To evaluate the in vitro role of oligodendrocyte specific Fgfr1 and IFN-β in 
oligodendrocyte proliferation and cytotoxicity. 
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3 MATERIALS AND METHODS 
 
3.1 MATERIALS 
3.1.1 Animals 
3.1.1.1 Mice provider 
 
Mice line Supplier Animal facility 
Fgfr1fl/fl 
The Jackson Laboratories, 
Bar Harbor, ME, USA 
JLU, Central Animal facility, 
Frankfurter straße, Giessen, 
Germany. 
PLP CreERT 
C57BL/6J 
 
3.1.1.2 Genetic background of mice strains 
 
Mouse strain Administration Abbreviation Genotype 
Plp/CreERT:Fgfr1fl/fl Vehicle (sunflower 
oil + ethanol) 
Control Homozygous 
Plp/CreERT:Fgfr1fl/fl Tamoxifen Fgfr1ind-/- Homozygous 
 
Tamoxifen was injected to 4 weeks old Plp/CreERT:Fgfr1fl/fl female mice for 5 
consecutive days to create the conditional knockout of Fgfr1 in oligodendrocyte 
lineage. Sunflower oil with ethanol without Tamoxifen was injected in age, gender 
matched mice from similar line (control).  
 
3.1.2 Cell lines 
 
Cell Line Provider 
Oli-neu Neurologie Klinikum, MS Research group, Gießen 
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3.1.3 Primary antibodies 
Name Host Reactivity 
Mol. 
Weight 
Method 
Artikle 
Nr 
Manufacturer 
Anti-pStat1 Rabbit H, M, R 
84/91 
kDa 
WB 9171s 
Cell Signaling Tech, 
MA, USA 
Anti-Stat1 Rabbit 
H, M, R, 
MK 
84/91 
kDa 
WB 9172 
Cell Signaling Tech, 
MA, USA 
Anti-
CNPase 
Mouse H, M, R 
46/48 
kDa 
WB ab6319 Abcam, UK 
Anti-MBP Mouse H, M, R, G 33 kDa WB ab62631 Abcam, UK 
Anti-PLP Rabbit H, M 
26/30 
kDa 
WB ab28486 Abcam, UK 
Anti-pERK 
p-44/42 
Rabbit 
H M R Hm 
Mk 
44, 42 WB 4370s 
Cell Signaling Tech, 
MA, USA 
Anti-Erk 
1/2 
Rabbit 
H, M, R, 
MK 
42/44 
kDa 
WB 9102 
Cell Signaling Tech, 
MA, USA 
Anti-Akt Rabbit 
H, M, R, 
MK 
60 kDa WB 9272 
Cell Signaling Tech, 
MA, USA 
Anti-pAkt 
(Ser473) 
Rabbit 
H, M, R, 
MK 
60 kDa WB 4060s 
Cell Signaling Tech, 
MA, USA 
Anti-Flg 
(C-15) 
(FGFR1) 
Rabbit H, M, R 110 kDa WB sc-121 
Santa Cruz Biotech, 
CA, USA 
Anti-Bek 
(C-17) 
(FGFR2) 
Rabbit H, M, R 120 kDa WB sc-122 
Santa Cruz Biotech, 
CA, USA 
Anti-
GAPDH 
Mouse 
Ca, H, M, 
R 
38 kDa WB MAB374 
Chemicon/ 
Millipore, CA; USA 
Anti-Trk B 
(794):sc12 
Rabbit H, M, R 145 kDa WB sc-12 
Santa Cruz Biotech, 
CA, USA 
Anti-BDNF Rabbit H, M, R 17, 13 kD WB sc-546 
Santa Cruz Biotech, 
CA, USA 
Anti 
pFGFR1 
Rabbit H M, R ~145 kDa WB 06-1433 Millipore, CA; USA 
Mac 3 
Clone 
M3/84 
Rat M staining IHC 553322 Pharmingen, USA 
B220 
clone RA3-
6B2 
Rat H, M staining IHC 557390 Pharmingen, USA 
CD3, clone 
CD3-12 
Rat M staining IHC 
MCA 
1477 
Serotec, UK 
Olig-2 Rabbit M staining IHC 18953 IBL, Japan 
Nogo A 
H300 
Rabbit H, M staining IHC Sc 25660 
Santa cruz Biotech, 
CA, USA 
MBP Rabbit M, R staining IHC 62301 Dako, Germany 
SMI 32 Mouse H, M.  staining IHC SMI32 SMI 
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3.1.4 Secondary antibodies 
Antibody Host Artikle Nr Manufacturer 
Anti-Rabbit-HRP Goat sc-2004 Santa Cruz Biotech, CA, USA 
Anti-Mouse-HRP Donkey sc-2318 Santa Cruz Biotech, CA, USA 
 
3.1.5 Kits 
Kit Manufacturer Artikle Nr Method 
BCA Protein Assay Kit  
 
Pierce® Thermo 
Scientific, IL, USA 
23225 
Protein 
quantification 
Cell Proliferation 
reagent WST-1 
Roche Applied Science, 
Mannheim, Germany 
11644807001 
Proliferation 
assay 
Cytotoxicity detection kit 
(LDH) 
Roche Applied Science, 
Mannheim, Germany 
11644793001 
Cytotoxicity 
assay 
DirectPCR Lysis 
Reagent (Tail) 
Peqlab, Erlangen, 
Germany 
31-121-T 
DNA 
isolation 
iTaqTM Universal 
SYBR® Green qPCR 
Master Mix  
Bio-Rad, CA, USA 172-5124 PCR 
QuantiTect® Reverse 
Transcription Kit 
Qiagen GmbH, Hilden, 
Germany 
205310 
Reverse 
Transcription 
SuperSignal® West 
Pico Chemiluminescent 
substrate 
Thermo Scientific, Il, 
USA 
34077 Western Blot 
Total RNA Isolation Kit 
NucleoSpin RNA II 
 Macherey-Nagel, 
Düren, Germany 
740955,3 
RNA 
Isolation 
 
3.1.6 Primers 
Primers were designed using NCBI primer designing tool and all primers were 
purchased from Eurofins Genomics, Ebersberg, Germany. 
 
3.1.6.1 Primers used for genotyping 
Gene (Primer) 5’              3’   Sequence 
PLP Cre PCR 
PLP transgene forward            GCGGTCTGGCAGTAAAAACTATC 
PLP transgene reverse            GTGAAACAGCATTGCTGTCACTT 
Cre Internal primer forward      CTAGGCCACAGAATTGAAAGATCT 
Cre Internal primer reverse      GTAGGTGGAAATTCTAGCATCATCC 
Fgfr1 lox 
Forward                                    GGACTGGGATAGCAAGTCTCTA 
Reverse                                    GTGGATCTCTGTGAGCCTGAG 
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3.1.6.2 Primers used for analysis 
Primer 5’               3’   Sequence 
TNF-α  
Forward   CGGTCCCCAAAGGGATGAGAAGT 
Reverse   ACGACGTGGGCTACAGGCTT 
IL-1β 
Forward  TACCTGTGGCCTTGGGCCTCAA 
Reverse  GCTTGGGATCCACACTCTCCAGCT 
IL-6 
Forward  CTCTGCAAGAGACTTCCA 
Reverse  AGTCTCCTCTCCGGACTT 
IL-12 
Forward  AGACCACAGATGACATGGTGA 
Reverse  ACGACGTGGGCTACAGGCTT 
iNOS 
Forward  TTGGAGGCCTTGTGTCAGCCCT 
Reverse  AAGGCAGCGGGCACATGCAA 
BDNF 
Forward  AAGGGCCAGGTCTGTTAAGC 
Reverse  GGTAAGAGAGCCAGCCACTG 
TrkB 
Forward  TGACGCAGTCGCAGATGCTG 
Reverse  TTTCCTGTACATGATGCTCTCTGG 
GAPDH 
Forward  GGATGGGTCCTCATGCTCAC 
Reverse  TGGTGCTGCAAGTCAGAGCAG 
TGF-β 
Forward  CTCCTGCTGCTTTCTCCCTC 
Reverse  GTGGGGTCTCCCAAGGAAAG 
SEMA3A 
Forward  GGATGGGTCCTCATGCTCAC 
Reverse  TGGTGCTGCAAGTCAGAGCAG 
Lingo1 
Forward  TCATCAGGTGAGCGAGAGGA 
Reverse  CAGTACCAGCAGGAGGATGG 
FGF2 
Forward  GGCTGCTGGCTTCTAAGTGT 
Reverse  ACTGGAGTATTTCCGTGACCG 
Fgfr1 
Forward CAGATGCACTCCCATCCTCG 
Reverse GGGAGCTACAGGGTTTGGTT 
PLP 
Forward GAGCAAAGTCAGCCGCAAAA 
Reverse CAAGCCCATGTCTTTGGCAC 
MBP 
Forward TCCATCGGGCGCTTCTTTAG 
Reverse TCTCGTGTGTGAGTCCTTGC 
CX3CR1 
Forward CTGCTCAGGACCTCACCATGT 
Reverse ATGTCGCCCAAATAACAGGC 
CX3CL1 
Forward GCGACAAGATGACCTCACGA 
Reverse TGTCGTCTCCAGGACAATGG 
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3.1.7 Ladders 
Marker Manufacturer 
PageRulerTM Plus Prestained 
Protein Ladder 
Fermentas, Invitrogen, Carlsbad, USA 
Fluorescent Long Range DNA Ladder Jena Bioscience, Jena, Germany 
 
3.1.8 Chemicals 
Compound Manufacturer 
10x PBS for cell culture (DPBS) Lonza, Köln, Germany 
2-Mercaptoethanol Sigma-Aldrich, Steinheim, Germany  
2-Propanol Sigma-Aldrich, Steinheim, Germany 
3% Hydrogen peroxide Carl Roth, Karlsruhe, Germany 
Acetic acid Merck, Darmstadt, Germany 
Agarose Bioline GmbH, Luckenwalde, Germany 
Ammonium Persulphate (APS) Carl Roth, Karlsruhe, Germany 
Bovine Serum Albumin (BSA) Merck, Darmstadt, Germany 
Bromophenol Blue Neolab, Heidelberg, Germany 
Citric acid Merck, Darmstadt, Germany 
complete Freund´s adjuvant Sigma, Steinheim, Germany 
Destilled water (Ecostrain®) Braun, Melsungen, Germany 
Dimethylsulfoxide (DMSO) Carl Roth, Karlsruhe, Germany 
Disodium-hydrogen-phosphate  Merck, Darmstadt, Germany 
DNase Qiagen, Hilden, Germany 
EDTA Carl Roth, Karlsruhe, Germany 
Eosin Merck, Darmstadt, Germany 
Eosin Carl Roth, Karlsruhe, Germany 
Ethanol 100% Sigma-Aldrich, Steinheim, Germany 
FBS PAA Laboratories, Pasching, Austria 
Glycerol Carl Roth, Karlsruhe, Germany 
Glycin Merck, Darmstadt, Germany 
Glyzerin Carl Roth, Karlsruhe, Germany 
Hematoxylin Carl Roth, Karlsruhe, Germany 
Isopropanol Merck, Darmstadt, Germany 
Ketamine Inersa Arzneimittel GmbH, Freiberg, 
Germany 
Luxol-Fast-Blue Sigma-Aldrich, Steinheim, Germany 
Magnesiumsulfate (MgSO4) Sigma Aldrich, Tachfkirchen, Germany 
Methanol Merck, Darmstadt, Germany 
MOG35-55 Charité Berlin, Berlin, Germany 
Mycobacterium tuberculosis Difco Microbiology, Michigan, USA 
NP40 US Biologicals, MA, Germany 
Paraformaldehyde (PFA) Sigma Aldrich, Taufkirchen, Germany 
Pertussis Toxin Calbiochem, Darmstadt, Germany 
Poly-L-Lysine Sigma-Aldrich, Steinheim, Germany 
Potassium chloride (KCL) Merck, Darmstadt, Germany 
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Potassiumdihydrogenphosphate  Merck, Darmstadt, Germany 
Protease Inhibitor cocktail Roche, Manheim, Germany 
Proteinase K Sigma-Aldrich, Missouri, USA 
RNAse free water Millipore corporation, MA, USA 
Rotiphorese Gel (30% acrylamide mix) Carl Roth, Karlsruhe, Germany 
Sodium chloride (NaCl) Carl Roth, Karlsruhe, Germany 
Sodium-dihydrogen-phosphate  Merck, Darmstadt, Germany 
Sodium hydrogen carbonate (NaHCO3) Merck, Darmstadt, Germany 
Sodiumdodecylsulfate (SDS) Neolab, Heidelberg, Germany 
Sodiumazid (NaN3) Merck, Darmstadt, Germany 
Sunflower oil Sigma-Aldrich, Steinheim, Germany 
Tamoxifen Sigma-Aldrich, Steinheim, Germany 
TEMED Carl Roth, Karlsruhe, Germany 
Tris HCl Carl Roth, Karlsruhe, Germany 
Tris. acetat-EDTA buffer (TAE) 10x Carl Roth, Karlsruhe, Germany 
Trishdroxymethyl aminomethan (Tris) Carl Roth, Karlsruhe, Germany 
Tryphanblue Carl Roth, Karlsruhe, Germany 
Trypsin (2.5g/l) Gibco, Invitrogen, Carlsbad, USA 
Tween 20 Merck, Darmstadt, Germany 
Xylazin 2% CEVA Tiergesunheit GmbH, 
Düsseldorf, Germany 
 
3.1.9 Laboratory consumables 
Consumables Manufacturer 
Cellstar® 6 Well and 24 well Cell 
Culture Plate 
GreinerBioOne, Frickenhausen, Germany 
Cellstar® Plastikpipettes (5 ml, 10 ml) GreinerBioOne, Frickenhausen, Germany 
Cellstar® U-shape with Lid, TC-Plate, 
96 well, sterile 
GreinerBioOne, Frickenhausen, Germany 
Cellstar® Flat bottom with Lid, TC-
Plate, 96 well, sterile 
GreinerBioOne, Frickenhausen, Germany 
Cellstar® 75 cm2 Cell cultur flasks GreinerBioOne, Frickenhausen, Germany 
Cellstar® 125 cm2 Cell cultur flasks GreinerBioOne, Frickenhausen, Germany 
Cell scrapper GreinerBioOne, Frickenhausen, Germany 
Cryobox 136x136x130 mm Ratiolab GmbH, Dreieich, Germany 
Cryo TubeTM vials (1,8 mL; 4,5 mL) Sarstedt AG & Co, Nümbrecht, Germany 
Falcon tubes (15ml, 50ml) Becton Dickinson, Heidelberg, Germany 
Glass Pasteur pipettes 150 mm Brand, Wertheim, Germany 
Ministart single use filter (0,2 μm, 0,45 
μm) 
Sartorius Stedim Biotech GmbH, 
Göttingen, Germany 
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Nitra-Tex® powder free gloves B. Braun Melsungen AG, Germany 
Parafilm Pechiney Plastic packaging, Menasha, WI 
Pipette tips without filter (10 μL, 100 
μL, 1000 μL) 
Sarstedt AG & Co, Nümbrecht, Germany 
Eppendorf tubes 1,5 mL, 2mL Eppendorf Vertrieb Deutschland GmbH, 
Wesseling-Berzdorf, Germany 
Eppendorf tubes 1,5 mL, 2mL (PCR 
clean- pyrogen & DNase free) 
Nerbe Plus GmbH, Winsen (Luhe), 
Germany 
Sterile PCR- clean pyrogen & DNase 
free with filter (10, 100, 200, 1000µl) 
Nerbe Plus GmbH, Winsen (Luhe), 
Germany 
Tissue culture dishes steril 35,0 /10mm GreinerBioOne, Frickenhausen, Germany 
UV-Spectroscopic cuvettes (RNA 
quantification) 
BioRad, München, Germany 
Falcon® Plastic pipettes 10ml, 5ml Becton Dickinson, Heidelberg, Germany 
Glasswares (different sorts) Fisherbrand; IDL; Schott&Gen; Simax 
Syringe 25ml for BSA  B. Braun Melsungen AG, Germany 
Nitrocellulose membrane GE Healthcare, AmershamTM Hybond 
ECL, Buckinghamshire, UK 
PCR Tube, cap-strips Applied Biosystems, Darmstadt, Germany 
 
3.1.10 Laboratory instruments 
Instrument Manufacturer 
Arpege 75, Liquid nitrogen tank  
Air Liquide Medical GmbH, Düsseldorf, 
Germany  
Axioplan 2 Fluorescence Microscope Carl Zeiss, Jena, Germany 
BEP 2000 Advance (ELISA-Reader)  
Dade Behring Marburg GmbH, Marburg, 
Germany 
Centrifuge type 2-6 Easia shaker 
Medgenix diagnostics 
Sigma-Aldrich Chemie GmbH, 
Taufkirchen, Germany 
Centrifuge Universal 32 R  Hettich GmbH, Kirchlengen, Germany 
ELISA-Reader Multiscan EX 
Thermo electron corporation, 
Langenselbold, Germany 
Fusion FX7 chemiluminescence 
system 
Peqlab Biotechnologie GmbH, Erlangen, 
Germany  
Hettich centrifuge (cooling) Hettich GmbH, Kirchlengen, Germany 
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Light Microscope for cell culture 
Carl Zeiss Microscopy GmbH, Oberkochen 
Germany 
Magnetic stirrer IKA Werke GmbH, Staufen, Germany 
Nalgene Cryo 1°C Freezing 
container  
Nalgene®, Germany 
Nanophotometer Implen GmbH, München, Germany 
Neubauer improved cell chamber Brand, Wertheim, Germany 
Neubauer improved Haemocytometer Brand, Wertheim, Germany 
Nuaire Biological Safety Cabinets 
Class II type A/B3 (Sterilbank) 
INTEGRA Biosciences GmbH, Fernwald, 
Germany 
pH-Meter Mettler Toledo GmbH, Giessen, Germany 
Pipette boy 
INTEGRA Biosciences GmbH, Fernwald, 
Germany 
Power pack 
Peqlab Biotechnologie GmbH, Erlangen, 
Germany  
Refrigerators and freezers Different companies 
Rotamax 120 (Shaker) 
Heidolph Instruments GmbH & Co. KG,   
Schwabach, Germany  
Sanyo Incu-safe incubator for cell 
culture 
Ewald Innovationstechnik GmbH, Bad 
Nenndorf, Germany 
SmartSpecTM Plus 
Spectrophotometer 
BioRad, München, Germany 
StepOne® Real-Time PCR system  Applied Biosystems, Darmstadt, Germany 
Surgical instruments Various companies 
Table top centrifuge EBA 20 Hettich GmbH, Kirchlengen, Germany 
Table top centrifuge micro 120 Hettich GmbH, Kirchlengen, Germany 
TissueRuptor 
Qiagen Instruments, Hombrechtikon, 
Switzerland 
Trans-Blot® SD Semi-dry transfer cell BIO RAD, München, Germany  
Trans-Blot® SD Semi-dry transfer cell BioRad, München, Germany 
Vortexer vortex-Genie2 
Heidolph Instruments GmbH & Co. KG,   
Schwabach, Germany  
Water bath Memmert GmbH + Co.KG, Germany 
Weighing balance 
Sartorius Stedim Biotech GmbH, 
Göttingen, Germany 
Western blotting system BioRad, München, Germany 
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3.1.11 Buffers 
Buffer Components Volume 
1X SDS-PAGE Running 
Buffer 
Rotiphorese® 10X 
Running Buffer 
H2O 
 
100 ml 
900 ml 
10x PBS (1 Liter) 
pH 7.4 
137 mM NaCl   
2 mM KH2PO4 
2.7 mM KCl  
10 mM Na2HPO4  
H2O 
80 g 
2.4 g 
2 g 
14.4 g 
1000 ml 
10x TBS (1 Liter) 
pH 7.2 to 7.6 
Tris   
NaCl  
H2O 
24.2 g 
87.7 g 
1000 ml 
1x TBS-Tween (TBST)  
(1 Liter) 
1x TBS  
0.1% Tween®20   
1000 ml 
1 ml 
Lysis Buffer (250ml) 
pH 7.4 
NaCl   
Tris  
EDTA  
Glycerol   
NP40  
NaN3 
2.19 g 
0.61 g 
0.07 g 
25 ml 
2.5 ml 
0.025 g 
6x SDS-PAGE Loading 
Buffer  
60 mM Tris-HCl (pH 6.8) 
2% SDS  
0.01% Bromophenol blue  
10% Glycerol  
ddH2O  
β-Mercaptoethanol 
36 ml 
60 ml 
60 mg 
60 ml 
144 ml 
65 µl/ml  
SDS-PAGE Transfer buffer  
(1 Liter) 
10x Running buffer  
Methanol  
ddH2O 
100 ml 
200 ml 
700 ml 
Blocking buffer (5% BSA)  
Bovine Serum Albumin 
BSA fraction V  
TBST 
5 g 
100 ml 
10x Trypsin EDTA 10x Trypsin 
ddH2O 
5 ml 
45 ml 
10% Ammonium Persulfate 
(APS) 
APS 
ddH2O 
1 g 
10 ml 
10% Sodiumdodecylsulfate 
(SDS) 
SDS 
ddH2O 
1 g 
10 ml 
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3.2.12 Softwares 
Fusion Bio1D software (Peqlab, Erlangen, Germany) 
Microsoft Office Professional Plus 2010 (Microsoft corporation, USA) 
SigmaPlot 10 software (Systat, San Jose, CA, USA) 
Systat 12 software (Systat, San Jose, CA, USA) 
Image J software (Image J 1.47d, National Institute of Health, USA) 
StepOne RealTime PCR Software v2.1 (Applied Biosystems, Darmstadt, Germany) 
Graph Pad Prism Software Version 5.01 (GraphPad Software, Inc. CA, USA). 
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3.2 METHODS 
 
3.2.1 Animal experiment procedures 
 
3.2.1.1 Mice 
Fgfr1-/-geflox flox (B6.129S4-Fgfr1tm5.1Sor/J), Plp-creERT (B6.Cg-Tg(Plp1-
cre/ERT)3Pop/J) and C57BL/6 mice were purchased from The Jackson Laboratories 
(Bar Harbor, ME, USA). Fgfr1-/- geflox flox (B6.129S4-Fgfr1tm5.1Sor/J) mice were 
crossbred with Plp-creERT (B6.Cg-Tg(Plp1-cre/ERT)3Pop/J) mice and backcrossed 
to C57BL/6J for at least 10 generations (Final mice line: B6.Cg-Tg(Plp1-
cre/ERT)3Pop Fgfr1tm5.1Sor). Mice were bread and grown in JLU-central animal facility, 
Frankfurter Straße 110, Gießen, Germany. All animal experiments were carried out in 
JLU central animal facility and analyzed in the Neurochemisches Labor, Department 
of Neurology, Gießen, Germany. 
 
3.2.1.2 Preparation of mice genomic DNA for genotyping 
The genotype was controlled by PCR (DirectPCR-Tail, Peqlab, Erlangen, Germany) 
using Fgfr1lox and Plp cre locus and confirmed by agarose gel electrophoresis. A 
small portion of (1 mm) tail or the ear from each mice were lysed in 200µl of Direct 
PCR tail reagent with proteinase K for 5-15 hours at 55 °C to digest the tissues and 
then for 45 minutes at 80 °C to deactivate Proteinase K. The tail lysate was 
centrifuged for 10 seconds and 1 µl has been used for genotyping PCR.  
 
3.2.1.3 Genotyping and identification of locus 
Genomic DNA from all mice (1 µl) was used in SYBR Green PCR and the primers for 
Fgfr1 and PLP/Cre locus were used (sections 3.2.1.4 and 3.2.1.5). Amplified PCR 
product was run in 1.5% agarose gel electrophoresis in 120v for 45 min (BioRad 
electrophoresis chamber) and bands were determined in Fusion Fx7 
chemiluminescence system (PEQLAB, Erlangen, Germany). 
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3.2.1.4 PCR master mix:  
                          Fgfr1 Locus                                PLP Cre Locus 
                   10 µl SYBR Green master mix     10 µl SYBR Green master mix      
7 µl H2O                                       5 µl H2O 
1 µl Forward Primer (Fgfr1)         1 µl Forward Primer (PLP) 
1 µl Reverse Primer (Fgfr1)         1 µl Reverse Primer (PLP) 
1 µl genomic DNA                        1 µl genomic DNA 
                                                     1 µl Forward Primer (CRE) 
                                                     1 µl Forward Primer (CRE) 
Total reaction        20 µl                                             20 µl 
 
3.2.1.5 Genotyping PCR thermal profile: 
 Fgfr1 locus PLP Cre Locus 
 Temp Time cycles Temp Time cycles 
Denaturing 95° C 5 min  
 
35x 
95°C 5 min  
 
35x 
 
Denaturing 95°C 30 s 95°C 30 s 
Annealing 64°C 1 min 51°C 1 min 
Elongation 72°C 1 min  72°C 1 min 
    72°C 2 min  
 
3.2.1.6 Fgfr1 conditional knockout creation  
To induce cre recombinase mediated deletion of Fgfr1 in oligodendrocytes, four 
weeks old Plp/CreERT:Fgfr1fl/fl (B6.Cg-Tg(Plp1-cre/ERT)3Pop Fgfr1tm5.1Sor) female 
mice were injected with 1 mg of tamoxifen i.p. (Sigma-Aldrich, Steinheim, Germany) 
in 100 µl sunflower oil/ethanol (Sigma-Aldrich, Steinheim, Germany) over 5 
consecutive days (later referred as Fgfr1ind-/- in this thesis) (Figure 9). Control mice of 
the same genotype received a sunflower oil/ethanol mixture. All animal experiments 
were approved by the local state authorities of Hesse, Giessen, Germany (GI 2008). 
 
Figure 9 Fgfr1 conditional knockout creation and tissue collection for Fgfr1 
knockout study. 
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3.2.1.7 Induction and clinical scoring of MOG35-55-induced EAE  
Mice were anesthesized for ~45 seconds by isoflurane and then EAE induction was 
done. EAE was induced in 8-12 weeks old female B6.Cg-Tg(Plp1-
cre/ERT)3Pop Fgfr1tm5.1Sor conditional knockout (Fgfr1ind-/- Tamoxifen, n = 13) and 
control mice (oil/ethanol vehicle, n = 13). Subcutaneous injection of 300 µg myelin 
oligodendrocyte glycoprotein peptide (MOG35-55; MOG peptide amino acids - 
MEVGWYRSPFSRVVHLYRNGK; Charité Hospital, Berlin, Germany) emulsified in 
complete Freund´s adjuvant (Sigma, Steinheim, Germany) containing 10 mg/ml 
Mycobacterium tuberculosis (Difco, Michigan, USA) were injected in 4 flanks. 
Intraperitoneal injections of 300 ng pertussis toxin (Calbiochem, Darmstadt, 
Germany) were done during immunization and 48 hours later. The clinical disease 
course was monitored daily until day 19 (acute phase) and until day 62 (chronic 
phase) (Figure 10). The EAE disease course was evaluated using a scale that 
ranged from 0 to 5: 0 = normal, 0.5 = distal tail weakness, 1 = complete tail 
weakness, 1.5 = mild hind limb weakness, 2 = ascending hind limb weakness, 2.5 = 
severe hind limb weakness, 3 = hind limb paralysis, 3.5 = hind limb paralysis and 
forelimb weakness, 4 = tetraparesis, 4.5 = tetraplegia and incontinence, to 5 = 
moribund/death. Three independent experiments were done. 
 
Figure 10  Experimental design of Fgfr1 conditional knockout creation, EAE 
induction, and clinical scoring till acute and chronic phase. 
 
3.2.1.8 EAE induction and Interferon beta-1a treatment (prevention study) 
EAE were induced as described in paragraph 1.5 and preventive treatment of 
Interferon beta 1a (IFN β-1a) were done. Post immunization with MOG peptide, 
control and Fgfr1ind-/- mice subcutaneously injected with 1µg/ml IFN β-1a (Merck 
Serono) from day 0 till day 7 p.i. (Figure 11). Mice were monitored till day 62 for EAE 
scoring as described in section 3.2.1.7. 
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Figure 11 Experimental design of Fgfr1 conditional knockout creation, EAE 
induction, IFN β-1a treatment and clinical scoring till chronic phase. 
 
3.2.2 Molecular biology methods 
 
3.2.2.1 RNA isolation 
At day 19 (acute phase) and day 62 (chronic phase) after EAE induction, mice were 
euthanized with CO2. The spinal cords and the spleens were removed, snap frozen in 
liquid nitrogen. The total RNA was isolated using NucleoSpin RNA II kit (Macherey-
Nagel, Düren, Germany) as manufacturer instructions. Briefly, frozen spleen and 
spinal cord were taken and RA1 lysis buffer with β-mercaptoethanol were added 
according to the weight of each tissue samples and homogenized with Tissue ruptor 
(Qiagen Instruments, Hombrechtikon, Switzerland). Lysate were added to 
NucleoSpin filter in collection tube and centrifuged for 11000g for 1 minute and flow 
through were mixed with 70% ethanol and then added to NucleoSpin RNA II column 
followed by 11000g for 30 seconds centrifugation. rDNAse mixer were added to the 
column and washed with wash buffer RA2 and RA3 then total RNA was eluted with 
50 µl RNAse free water. Total RNA concentration was quantified in SmartSpec 
spectrophotometer. 
 
3.2.2.2 Reverse transcription and cDNA synthesis 
cDNA was synthesized from 1 µg/ml of total RNA using the QuantiTect® Reverse 
Transcription Kit (Qiagen GmbH, Hilden, Germany). In 20 µl of diluted 1 µg/ml of total 
RNA 3 µl genomic DNA wipeout buffer was added and incubated at 42 °C for 2 
minutes, then cDNA synthesis master mix (5x RT buffer - 4 µl, RT Primer - 1 µl, RT 
master mix - 1 µl) was added followed by incubation at 42 °C for 30 minutes and 95 
°C for 3 minutes. Synthesized cDNA were stored -20 or -80 °C until use.  
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3.2.2.3 Relative real time-PCR quantification 
Quantitative PCR detection of gene expression in the spinal cord and spleen were 
measured using iTaqTM Universal SYBR® Green qPCR Master Mix (Bio-Rad, CA, 
USA) by 40 cycles at an annealing temperature of 60 °C in the StepOne® Real-Time 
PCR system (Applied Biosystems, Darmstadt, Germany). Primers were designed by 
NCBI nucleotide Primer designing tool and primers were synthesized in Eurofins-
Genomics (Eurofins MWG Synthesis Gmbh, Ebersberg, Germany). The 
quantification of target genes was done using the primers listed on table and the 
PCR composition of 10 µl Mastermix (iTaqTM Universal SYBR® Green), 1 µl forward 
primer, 1 µl reverse primer, 7 µl H2O and 1 µl of cDNA. GAPDH was used as the 
internal control gene, and the comparative ∆∆CT method (∆CT= target gene - 
housekeeping gene; ∆∆CT = 2^-∆CT) was used to evaluate the relative quantification 
of gene expression. 
 
3.2.3 Protein biochemistry 
 
3.2.3.1 Protein extraction and quantification 
Mice for knockout study (Figure 9), acute and chronic EAE (Figure 10) were 
euthunized by CO2 and different CNS tissues (spinal cord, brain stem, cortex, 
cerebellum, hippocampus, rest of the brain) were separated. Tissues were 
homogenized in lysis buffer (150 mM NaCl, 20 mM Tris HCl, 1 mM EDTA, 10% 
glycerol, 1% NP40, 0.01% sodium azide) with Tissue ruptor (Qiagen Instruments, 
Hombrechtikon, Switzerland). The lysate were centrifuged at 4 °C for 30 minutes at 
14000 rpm and supernatant were collected. The amount of protein was estimated 
using BCA assay as manufacturer instructions (Pierce® BCA Protein Assay Kit, 
Thermo Scientific, IL, USA). Briefly 25 µl of 1:10 diluted protein samples were taken 
as triplicate in 96 well flat bottom plate and 200 µl of Reaction Reagent was added 
and incubated for 30 minutes at 37 °C. The plate was measured in ELISA reader at 
the nanometer range of 540 nm. Measured protein level was normalized to 2 µg/µl 
concentrations in lysis buffer and stored at -20 °C until use.  
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3.2.3.2 SDS-PAGE and western blot 
Protein loading buffer 6x was added to 30 µl of protein sample (60 µg) and boiled for 
5 minutes at 95 °C. Normalized protein was loaded and separated by 10% SDS-
PAGE (Rotiphorese® Gel 30, 10x SDS-PAGE, Carl Roth Gmbh, Karlsruhe, 
Germany), transferred (Trans Blot, semi dry transfer cell, BioRad) to a nitrocellulose 
membrane (GE Healthcare, AmershamTM Hybond ECL, Buckinghamshire, UK) and 
blocked with 5% BSA for 1 hour. The membranes were incubated overnight at 4 °C 
with the primary antibodies diluted in 1x TBST buffer and washed with TBST for 5 
minutes for 3 times. Membranes were then incubated for 1 hour at 4 °C with 
secondary antibody diluted in 1x TBST followed by 3 times TBST wash for each 5 
minutes. Then membranes were developed using Super Signal West Pico 
chemiluminescent substrate (Thermo, Pierce Biotechnology, Rockford, IL, USA) in 
Fusion Fx7 chemiluminescence system (PEQLAB, Erlangen, Germany). GAPDH was 
used as a loading control; proteins were analyzed by use of the Fusion Bio1D 
software (PEQLAB, Erlangen, Germany).   
 
3.2.4 Histopathology and immunohistochemistry 
 
3.2.4.1 Mice perfusion 
Intraperitoneal injection of ketamin and xylazin was done in Fgfr1ind-/- mice and 
controls for anesthesia, mice were transcardially perfused with 4% paraformaldehyde 
at day 18-19 (acute phase) and day 62 (chronic phase) after EAE induction. The 
spinal cord and brain were removed and embedded in paraffin blocks. Spinal cord 
and brain tissues were fixed and sections were made with 1 µm in thickness for 
histopathology and immunohistochemistry.  
 
3.2.4.2 Histology 
For histopathology, paraffin sections were evaluated for inflammatory infiltrates 
(hematoxylin and eosin stain), demyelination (Luxol fast blue/periodic acid-Schiff 
stain) and axonal density (Bielschowsky staining). Histological evaluation was done 
with a light microscope (Carl Zeiss, Germany). 
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3.2.4.3 Hematoxylin and Eosin staining (H & E) 
Inflammation in the spinal cord in acute and chronic EAE was analyzed by H & E 
staining. Briefly, slides were incubated in xylene for deparafination followed by 
ethanol hydration. Then slides were stained in Hematoxylin for 5 minutes, washed 
with water and then stained in eosin for 5 minutes. Slides were mounted with 
mounting medium in glass cover slip after dehydration and xylene rinses. Detailed 
procedure is presented in schematic diagram (Figure 12).  
 
Figure 12 Schematic procedure of H & E staining. 
 
3.2.4.4 Luxol fast blue/periodic acid-schiff stain (LFB / PAS) 
Demyelination in acute and chronic EAE spinal cord was analyzed by LFB/PAS 
staining. Tissue sections were deparafinized with xylene and then hydrated in 
ethanol followed by overnight incubation in luxol fast blue stain at 56 °C. Slides were 
mounted with mounting medium in glass cover slip after hydration and xylene rinses. 
Detailed procedure is presented in schematic diagram (Figure 13). The final % value 
for demyelination was calculated using equation listed below:   
 
 
                                                        Demyelinated area in white matter 
            Demyelinated area (%) =                                                               X  100 
                                                                 Total white matter area 
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Figure 13 Schematic procedure of Luxol fast blue/PAS staining. 
 
3.2.4.5 Bielschowsky (Silver staining) 
Axonal density in acute and chronic EAE spinal cord was analyzed by Bielschowsky-
silver staining. Deparafinized and hydrated sections were incubated with 20% silver 
nitrate (AgNO3, Roth) for 20 minutes in dark and the reaction was stop by water 
wash. Then the sections were incubated for 2 minutes in 2% Na-Thiosulfate (Sigma 
Aldrich) followed by water wash. Sections were dehydrated in ethanol and mounted 
with cover glass.  
 
3.2.4.6 Immunohistochemistry 
For immunohistochemistry, sections were deparafinized in xyline, hydrated, 
endogenous peroxidase was blocked for 10 minutes with 3% hydrogen peroxide and 
pretreated with citrate buffer (10 mM, pH 6) over 5 minutes for 3 times. Paraffin 
sections were incubated with 10% FCS and stained overnight for activated microglia-
macrophage (Mac 3, clone M3/84, 1:200, Pharmingen, San Diego, CA, USA), 
activated B cells (B220, clone RA3-6B2, 1:200, Pharmingen, San Diego, CA, USA), 
and T cells (CD3, clone CD3-12, 1:150, Serotec, Oxford, UK). Quantitative analysis 
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of oligodendrocyte populations in the spinal cord and brain cortex region was 
performed by olig2, nogoA immunostaining (olig 2, 1:300, IBL, Gunma, Japan; 
nogoA, 1:300, Santa Cruz Biotech, CA, USA). Respective secondary antibodies (Mac 
3-goat anti-rat, 1:100, B220-goat anti-rat 1:200, CD3 and olig2, nogoA-goat anti-
rabbit-1:250) and avidin-biotin method was used and the signals were detect with 
DAB. Microscopic images were captured using a Zeiss light microscope (Germany) 
and analyzed using the Axio vision software. 
 
3.2.5 Cell culture experiments 
Oli-Neu (mice oligodendrocyte adherent cell line) was used in this study. Cell line 
was cultured at 37 °C in 5% CO2. Oli-neu cell line were maintained in DMEM medium 
supplemented with B27 supplement (Invitrogen), 0.011% sodium pyruvate, 500 nM 
Tri-lodo-L-Thyronine, 520 nM L-Thyroxine. Poly-L-Lysine was coated in 75 cm2 
culture flask for at least 5 hours or overnight and washed with 1x PBS for 3 times 
before use. Plates were stored at 4 °C until use. Oli-neu cells were seeded in the 
Poly-L-Lysine coated flask and above 80% confluent flasks were used for 
experiments. Cell lines were passaged by 1x PBS wash followed by 1% Trypsin at 37 
°C for 1 minute incubation.  
 
3.2.5.1 Fgfr1 inhibition and stimulants in oligodendrocyte cell line 
PD166866, a potent Fgfr1 tyrosine kinase inhibitor was used in this study. PD166866 
was dissolved in DMSO and above 80% confluent cells were treated with 10 µM 
concentration of PD166866 for 2-3 hours. Interferon β-1a (IFN β-1a, 400 ng/ml, 
Rabiff) and Interferon β-1b (IFN β-1b, 500 ng/ml, Betaferon) were used to analysis 
the impact of both Interferon β-(1a and b) and Fgfr1 ablation in oligodendrocyte and 
neuronal cell line.  
 
3.2.5.2 Cell proliferation assay 
Oli-neu oligodendrocyte cells were seeded in 96 well plates (poly-L-lysine coated) in 
a final volume of 100 µl/well (1x105 cells/ml), maintained in culture until the cells 
tightly adhere to the bottom of the plates.  Then the old medium was removed and 
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the cells were incubated for 24 hours with fresh medium containing FGF (20 ng/ml), 
PD166866 (10 µM), IFN β-1a (400 ng/ml, Rabiff), IFN β-1b (500 ng/ml, Betaferon), 
IFN β-1a + PD166866 and IFN β-1b + PD166866. Then 10 µl of WST-1 reagent (Cell 
proliferation reagent WST-1, Roche applied science, Indianapolis, IN) was added in 
each well and the assay was carried out as mentioned in the instructions provided by 
the manufacturer. Plates were shaken thoroughly for 1 minute on a shaker and 
incubated for 4 hours at standard cell culture conditions. The colour developed from 
the soluble formazan dye cleaved from the tetrazolium salt WST-1 was measured at 
an absorbance of 420-480 nm in an ELISA reader. 100 µl of assay medium was 
taken as blank control for measuring the background absorbance. All experiments 
were carried out in triplicates. To calculate proliferation, mean absorbance was 
calculated and background absorbance (medium alone) subtracted from each value. 
The percentage of specific proliferation was quantified using the following calculation: 
% Proliferation = (experimental release / spontaneous release) x 100. 
 
3.2.5.3 Cell cytotoxicity assay 
Possible cytotoxicity effects of Fgfr1, IFN β-1a and IFN β-1b in oli-neu cells were 
measured using LDH cytotoxicity assay according to the manufacturer’s instructions 
(Roche applied science, Indianapolis, IN). Cells were seeded in optically clear flat-
bottomed 96 well plates in the concentration of 1x105 cells/ml. 100 µl of this 
suspension is filled in the 96 well plates.  Then, old medium was discarded and 200 
µl medium containing FGF, PD166866, IFN β-1a, IFN β-1b was added and incubated 
for another 24 hours at standard cell culture conditions.  Assay medium was used as 
background control, 100 µl cell suspensions and 100 µl assay medium as low control. 
To determine the maximum amount of LDH enzyme activity, 2% Triton-X 100 was 
used as high control. After 24 hours, the plate was centrifuged at 250 g for 10 
minutes. From this, 100 µl supernatant was transferred into new 96-well plates and 
100 µl assay reagent was added and incubated for 30 minutes at room temperature 
in dark. The amount of color produced due to the release of LDH enzyme was read in 
490 nm in an ELISA reader. All the assays were carried out in triplicates, average 
absorbance values of the triplicates were calculated and background control 
subtracted.  Cytotoxicity (%) was calculated as follows: % Cytotoxicity = 
[(Experimental value – low control value)/ (High control value – low control value)] x 
100 
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3.2.5.4 Protein extraction  
Oli-neu cells were grown in Poly-L-Lysine coated 75 cm2 culture flask above 80% 
confluence. Culture medium was removed from the cells then fresh medium was 
added with respective treatments (10 µM PD166866) for 2-3 hours. Cells were 
stimulated with 25 ng/ml basic FGF, IFN β-1a and or IFN β-1b with or without Fgfr1 
inhibition (10 µM PD166866) for 5 minutes. Then medium was removed from the 
culture medium and washed with cold 1x PBS followed by tripsination. Cells were 
scraped from the flask and centrifuged for 3500 rpm, 15 minutes at 4 °C. Supernatant 
was discarded and cell pellet were lysed with lysis buffer and incubated in ice for 30 
minutes. Then the cell lysate was centrifuged at 14000 rpm in 4 °C for 30 minutes, 
supernatant were collected and stored at -20 °C until analysis.  
 
3.2.5.5 Protein quantification and western blot 
Protein quantification (BSA protein assay), SDS-PAGE and western blot procedure 
were followed as described in sections 3.2.3.1 and 3.2.3.2.  
 
3.2.6 Statistics 
All analyses were performed blinded to the genotype. All mice and samples were 
included into the analysis. Statistical analysis for differences between the genotypes 
in the clinical course and histological data was performed using the Mann-Whitney U 
test. T-test was used to analyze reverse transcription-PCR and protein data. 
Unpaired t-tests were used for other experiments. Statistical significance was set at P 
≤ 0.05. Statistical analysis was performed using GraphPad Prism version 4.00 for 
Windows (GraphPad Software, San Diego, California, USA) and Systat 12 software 
(Systat, San Jose, CA, USA). Graphs were prepared using the Sigmaplot 10 software 
(Systat, San Jose, CA, USA) and GraphPad Prism version 4.00 for Windows 
(GraphPad Software, San Diego, California, USA). Values are expressed as mean ± 
standard error of mean.  P values of * P < 0.05, **P < 0.005, ***P < 0.001 were 
considered as significant.  
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4 RESULTS 
 
4.1 Oligodendrocyte specific Fgfr1 knock down study 
 
4.1.1 Conditional deletion of oligodendrocyte specific Fgfr1 in C57BL/6J mice: 
genotype and phenotype confirmation  
Complete deletion of Fgfr1 is lethal in embryonic day 6-10. Fgfr1 conditional knockout 
is the appropriate method to study the role of Fgfr1 in specific cell type or in tissue. 
Tamoxifen inducible Cre mediated deletion of Fgfr1 in oligodendrocyte under PLP 
promoter achieved in B6.Cg-Tg(Plp1-cre/ERT)3Pop Fgfr1tm5.1Sor mice line. Mice with 
floxed Fgfr1 was mated with transgenic mice expressing Cre recombinase under the 
control of PLP promoter which is specific to oligodendrocytes. This PLP promoter 
allows excision of floxed alleles (Fgfr1) in oligodendrocyte lineage cells in CNS. 
Genotype was confirmed with primers for PLP Cre and Fgfr1 loxP (Figure 14). There 
were no effect on mortality, body weight, and specific phenotype changes were 
observed in Fgfr1 conditional knockout mice. 
 
Figure 14 Genotype confirmation of Fgfr1 lox and PLP Cre locus from mice tail 
complete DNA by PCR. Mice tails were lyzed with direct tail lysis buffer and 
genotype was carried with Fgfr1 lox (A) and PLP Cre locus (B). PCR amplified 
products were confirmed with agarose gel electrophoresis. Representative agarose 
gel images were shown. WT: wild type C57Bl/6J control, +ve: positive control. 
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4.1.2 Characterization of oligodendrocyte specific Fgfr1 signalling in C57Bl/6J 
mice 
To characterize the role of oligodendrocyte specific Fgfr1, Tamoxifen inducible Cre 
mediated deletion of Fgfr1 was achieved in 4 weeks old female mice (B6.Cg-Tg(Plp1-
cre/ERT)3Pop Fgfr1tm5.1Sor: Fgfr1lox+ve and Cre+ve mice). Four weeks old B6.Cg-
Tg(Plp1-cre/ERT)3Pop Fgfr1tm5.1Sor mice were injected with Tamoxifen for 5 
consecutive days (referred as Fgfr1ind-/-). 15 days later Tamoxifen injection, spinal 
cord and CNS tissues were removed and analyzed by western blot. Whole lysate of 
cortex and spinal cord from control and Fgfr1ind-/- mice shows the same level of Fgfr1 
(cortex P = 0.8845, spinal cord P = 0.2711) and Fgfr2 (cortex P = 0.1417, spinal cord 
P = 0.3052) expression (Figure 15 A and B). Three bands of different splice variant 
have been observed for Fgfr2 in cortex and spinal cord (Figure 15 A and B). There 
was no compensatory up-regulation of Fgfr2 expression detected in Fgfr1ind-/- mice 
spinal cord by western blot analysis.  
 
4.1.3 Effect of Fgfr1 ablation in oligodendrocytes on Fgfr1 signal cascade 
Fgfr1 signal cascade mainly involved in ERK and AKT pathways which enhance the 
proliferation and survival respectively. To analyze the effect of oligodendrocyte 
specific Fgfr1 ablation in the Fgfr1 signalling pathways, whole lysates of cortex and 
spinal cord were analyzed from control and Fgfr1ind-/- mice. There were increased 
expression of ERK and AKT phosphorylation was seen in cortex (pERK: P = 0.6563, 
pAKT: P = 0.259) but not significant (Figure 16 A) and spinal cord (pERK: P = 0.029, 
pAKT: P = 0.045) of Fgfr1ind-/- mice compared to control mice (Figure 16 B).  
 
4.1.4 Effect of Fgfr1 ablation in oligodendrocytes on TrkB expression 
To analyze the influence of oligodendrocyte specific Fgfr1 on TrkB expression, whole 
protein lysates of cortex, spinal cord, cerebellum and brainstem from control and 
Fgfr1ind-/- mice were analyzed by western blot. Increased expression of TrkB was 
observed in cortex (P ≤ 0.05) and spinal cord (P = 0.073) of Fgfr1ind-/- mice (Figure 17 
A and B). There was no regulation in TrkB expression in Fgfr1ind-/- mice cerebellum (P 
= 0.31), whereas down regulation of TrkB expression was seen in Fgfr1ind-/- brainstem 
(P ≤ 0.0001).  
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Figure 15  Fgfr´s expression in Fgfr1ind-/- mice CNS. Whole protein lysate of cortex 
and spinal cord were checked in western blot for Fgfr1 and Fgfr2 expression. There 
is no difference in the expression of Fgfr1 and Fgfr2 in Fgfr1ind-/- cortex (A) and spinal 
cord (B) whole lysate. Fgfr1 with 110 and 140 kDa, and Fgfr2 show 3 bands of 
different splice variants (120 and nearby). Representative blot and quantification 
were shown. n.s. = not significant. Values are expressed as mean ± standard error of 
mean. 
         Results   
48 
 
 
Figure 16 Expression pattern of ERK and AKT phosphorylation in control and 
Fgfr1ind-/- mice cortex and spinal cord. Representative blot and quantification were 
shown. Phosphorylation of ERK and AKT in cortex showed no regulation (A). 
Increased expression of ERK and AKT phosphorylation were seen in spinal cord of 
Fgfr1ind-/- mice (B). P values of * P < 0.05, **P < 0.005, ***P < 0.001 were considered 
as significant. Values are expressed as mean ± standard error of mean.  
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Figure 17 TrkB protein expression in different CNS region of control and 
Fgfr1ind-/-. Proteins were isolated from CNS region (cortex, spinal cord, cerebellum 
and brainstem) and analyzed for TrkB protein expression by western blot. 
Representative blots and respective quantification were shown (A: cortex and spinal 
cord, B: cerebellum and brain stem). P values of * P < 0.05, **P < 0.005, ***P < 0.001 
were considered as significant. Values are expressed as mean ± standard error of 
mean. 
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4.1.5 Effect of Fgfr1 ablation in MBP expression in Fgfr1ind-/- 
To analyze the effect of oligodendrocyte specific Fgfr1 ablation in MBP expression in 
tissue level, spinal cord from control and Fgfr1ind-/- mice was perfused and 
immunostained with MBP antibody and analyzed semi quantitatively. There were no 
differences in the expression of MBP in tissue level was seen in spinal cord of 
Fgfr1ind-/- mice compared to control mice (Figure 18).  
 
 
Figure 18 Myelin basic protein expressions in control and Fgfr1ind-/- mice. 
Immunohistochemistry analysis shows there were no differences in the expression of 
MBP in control and Fgfr1ind-/- mice spinal cord. n.s. = not significant. Values are 
expressed as mean ± standard error of mean. 
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4.1.6 Effect of Fgfr1 ablation in oligodendrocytes on cell population 
To analyze the effect of oligodendrocyte specific Fgfr1 ablation on oligodendrocyte 
cell population, olig2 and nogo A positive oligodendrocyte lineage cells were counted 
from control and Fgfr1ind-/- mice spinal cord by immunohistochemistry. There were no 
differences in the olig 2 and nogo A positive oligodendrocyte lineage cell population 
in Fgfr1ind-/- mice spinal cord compared to control mice (Figure 19). 
 
 
Figure 19 Olig 2 and nogoA positive oligodendrocyte lineage cells in control 
and Fgfr1ind-/- mice spinal cord. There are no differences in the number of olig2 and 
nogoA positive oligodendrocyte cell population in spinal cord of Fgfr1ind-/- mice. 
 
4.2 EAE in Fgfr1ind-/- and control mice 
 
4.2.1 EAE scoring  
EAE was induced in control and Fgfr1ind-/- mice with MOG35-55 peptide. All mice were 
monitored and scored EAE clinical symptoms. Both mice groups show distinct clinical 
symptom and EAE score were evaluated as described in method section 3.2.1.7. 
Figure 20 shows the clinical symptoms of EAE mice.  
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Figure 20 Clinical symptoms of MOG35-55 peptide induced EAE in control mice. 
Tail and hind limb paralysis and mild fore limb weakness of EAE mice shown in plain 
(A-C) and net surface (D-H).  
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4.2.2 Fgfr1ind-/- mice show a milder EAE disease course  
Mice with oligodendroglial Fgfr1 deletion (Fgfr1ind-/-) were analyzed for their 
susceptibility to MOG35-55 peptide EAE induction. EAE was induced in 13 eight to 
twelve-week-old female Fgfr1ind-/- mice and compared with 13 age- and sex-matched 
controls. There were no differences in body weight between Fgfr1ind-/- and control 
mice (Figure 21). Figure 22 and table 4 shows the summary of the EAE score in 
control and Fgfr1ind-/- mice.  The onset of clinical symptoms was on day 10.0 ± 0.24 in 
controls and on day 11.5 ± 0.21 in Fgfr1ind-/- mice (P < 0.001). The mean maximum 
disease score was less in Fgfr1ind-/- mice (P ≤ 0.05). From day 33 p.i. (with exception 
of days 47 and 48) Fgfr1ind-/- mice showed a milder disease course than controls (P ≤ 
0.05). In this disease phase, Fgfr1ind-/- mice presented with a mild paraparesis 
whereas controls still suffered from a severe paraparesis. Also, the cumulative EAE 
score was higher in controls (P ≤ 0.05; Figure 22 B). Disease incidence was 100%. 
No effect of gene deletion on mortality was observed.  
 
 
Figure 21 Mean weights of control and Fgfr1ind-/- mice after MOG35-55 EAE 
induction. Both mice group showed weight loss in acute phase of the EAE disease 
and later in chronic phase, both mice group gained weight.  
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Figure 22 Conditional deletion of Fgfr1 in oligodendrocyte suppresses the 
MOG35-55 induced EAE. A) Fgfr1
ind-/- mice showed a delayed onset of disease (P < 
0.001). Milder disease course was found in Fgfr1 conditional knockout mice, until day 
27 p.i. Whereas from day 28 onwards, conditional Fgfr1ind-/- mice showed significant 
milder disease course (P < 0.001) till the end of chronic phase.  B) Cumulative score 
of chronic EAE till day 62 p.i. was less in Fgfr1ind-/- mice (P < 0.001). n = 13, data are 
presented as mean ± SEM. 
A 
B 
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Table 4 Clinical characteristics of MOG35-55-induced EAE in Fgfr1
ind-/- mice 
Mice Number Incidence 
EAE clinical score 
M
o
rt
a
lit
y
 
Disease 
onset (day) 
Maximum 
score 
Day 19 Day 62 
control 13 100% 9 .9 ± 0.2 4.5 3.0 ± 0.2 3.0 ± 0.2 Nil 
Fgfr1ind-/- 13 100% 11.4 ± 0.2 4.0 2.5 ± 0.3 1.3 ± 0.3 Nil 
Conditional deletion of Fgfr1 in oligodendrocyte lineage showed late onset of EAE 
clinical sign. Whereas from day 19 p.i. Fgfr1ind-/- mice showed milder disease course 
till end of the experiment.  
 
4.2.3 Reduced demyelination and increased axonal density in Fgfr1ind-/- mice  
The differences in the clinical course were most evident for the chronic phase of EAE 
(Figure 22, Table 4 and 5). As the next step, Fgfr1ind-/- mice were assessed for their 
susceptibility to demyelination and axonal density in spinal cord white matter. 
Demyelination was evaluated by Luxol fast blue staining and axonal density by 
Bielschowsky staining. In the acute phase no difference in demyelination was 
observed between Fgfr1ind-/- mice and controls (Figure 24 A, B and C). At this time 
point, axonal density was higher in Fgfr1ind-/- mice than in controls (P ≤ 0.05) (Figure 
25 A, B and C). In the chronic phase Fgfr1ind-/- mice showed less demyelination (P ≤ 
0.05; Figure 24 D, E and F) and a higher axonal density (P ≤ 0.05; Figure 25 D, E 
and F).  
Table 5 Histopathological analysis of spinal cord from EAE mice. 
Pathology 
Day 19 
P-
value 
Day 62 
P-
value control Fgfr1ind-/- control Fgfr1ind-/- 
Inflammatory 
index 
1.83 ± 
0.8 
0.97 ± 
0.4 
P = 
0.4147 
2.4 ± 0.4 
1.01 ± 
0.4 
P = 
0.0163 
Demyelination 
(%) 
5.76 ± 
1.4 
7.02 ± 
3.1 
P = 
0.7353 
29.7 ± 
10.6 
5.6 ± 9.8 
P = 
0.0453 
Axonal density 
(%) 
44.93 
± 3.2 
73.07 ± 
2.1 
P = 
0.002 
23.8 ± 
11.8 
63.7 ± 
17.2 
P = 
0.030 
Blinded quantification of inflammation (H & E), demyelination by LFB/PAS and axonal 
density (silver staining) in spinal cord of controls and Fgfr1ind-/- mice in EAE. Data are 
presented as mean ± SEM. 
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4.2.4 Inflammation in Fgfr1ind-/- mice is characterized by reduced numbers of 
lymphocytes and macrophages/microglia   
To study the underlying cellular mechanisms that drive demyelination and axonal 
damage, the degree of inflammation was analyzed in spinal cord white matter lesions 
on H&E stained sections of Fgfr1ind-/- mice and littermate controls. In the acute phase 
the inflammatory index was not different between Fgfr1ind-/- mice and controls (Figure 
23 A, B and C), whereas in the chronic phase the inflammatory index was reduced in 
Fgfr1ind-/- mice (P ≤ 0.05; Figure 23 D, E and F). With regard to cellular infiltration the 
number of CD3 (+) T cells was not affected by Fgfr1 deletion in the acute phase of 
EAE (Figure 26 A, B and C). However, the number of B220 (+) B cells (P ≤ 0.05; 
Figure 27 A, B and C) and Mac3 (+) cells (P ≤ 0.05; Figure 28 A, B and C) was 
reduced in Fgfr1ind-/- mice compared to controls. In the chronic phase a reduction of 
CD3 (+) T cells (P ≤ 0.05; Figure 26 D, E and F), B220 (+) B cells (P ≤ 0.05; Figure 
27 D, E and F) and Mac3 (+) cells (P ≤ 0.05; Figure 28 D, E and F) was observed 
compared with controls. Table 6 shows the summary of immune cell infiltration in 
acute and chronic EAE spinal cord. 
 
Table 6 Immune cell infiltrations in spinal cord of EAE mice. 
Disease 
pathology 
Acute EAE Chronic EAE 
control Fgfr1ind-/- P-value control Fgfr1ind-/- P-value 
CD3 (+) T 
cells 
624 ± 200 284 ± 80 
P = 
0.19 
160 ± 43 27 ± 9 P ≤ 0.05 
B220 (+)  B 
cells 
625 ± 128 164 ± 56 
P ≤ 
0.05 
273 ± 51 48 ± 16 P ≤ 0.05 
Mac3 (+) 
Macrophages 
2455 ± 
306 
1080 ± 
68 
P ≤ 
0.05 
1650 ± 
465 
243 ± 47 P ≤ 0.05 
Blinded quantification of immune cell infiltration of T cells, B cells and macrophages 
in spinal cord of controls and Fgfr1ind-/- mice in acute and chronic EAE. Data are 
presented as mean ± SEM. 
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Figure 23 Histopathological analysis of acute and chronic EAE (H and E). 
Inflammatory index in the spinal cord sections of acute (A, B and C) and chronic (D, 
E and F) EAE in controls (A, D) and Fgfr1ind-/- mice (B, E). Representative images of 
spinal cord sections are shown. The inflammatory index (C and F) was less in 
Fgfr1ind-/- mice compared to control. Bar: 200 µm. n = 3, data are presented as mean 
± SEM.  
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Figure 24 Histopathological analysis of acute and chronic EAE (LFB/PAS). 
Demyelination in the spinal cord sections of acute (A, B and C) and chronic (D, E and 
F) EAE in controls (A, D) and Fgfr1ind-/- mice (B, E). Representative images of spinal 
cord sections are shown. The percentage of demyelination (F) was less in Fgfr1ind-/- 
mice compared to control in chronic EAE. Bar: 200 µm. n = 3, data are presented as 
mean ± SEM.  
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Figure 25 Histopathological analysis of acute and chronic EAE (Silver staining). 
Axonal density in the spinal cord sections of acute (A, B and C) and chronic (D, E 
and F) EAE in controls (A, D) and Fgfr1ind-/- mice (B, E). Representative images of 
spinal cord sections are shown. Percentage of axonal density (C and F) was higher in 
Fgfr1ind-/- mice compared to control. Bar: 200 µm. n = 3, data are presented as mean 
± SEM.  
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Figure 26 Immune cell infiltration in acute and chronic EAE spinal cord (T 
cells). CD3 (+) T cells in white matter lesions of spinal cord sections in acute (A, B 
and C) and chronic (D, E and F) EAE in controls (A, D) and Fgfr1ind-/- mice (B, E). 
Representative images of spinal cord sections are presented. The number of CD3 (+) 
T cells per mm2 was less in Fgfr1ind-/- mice compared with controls in chronic EAE 
(F). Bar: 200 µm, 20 µm (insert). n = 3, data are presented as mean ± SEM.  
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Figure 27 Immune cell infiltration in acute and chronic EAE spinal cord (B 
cells). B220 (+) B cells in white matter lesions of spinal cord sections in acute (A, B 
and C) and chronic (D, E and F) EAE in controls (A, D) and Fgfr1ind-/- mice (B, E). 
Representative images of spinal cord sections are presented. The number of B220 
(+) B cells per mm2 was less in Fgfr1ind-/- mice compared with controls in acute and 
chronic EAE (C and F). Bar: 200 µm, 20 µm (insert). n = 3, data are presented as 
mean ± SEM.  
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Figure 28 Immune cell infiltration in acute and chronic EAE spinal cord 
(Macrophages). Mac3 (+) Macrophages in white matter lesions of spinal cord 
sections in acute (A, B and C) and chronic (D, E and F) EAE in controls (A, D) and 
Fgfr1ind-/- mice (B, E). Representative images of spinal cord sections are presented. 
The number of Mac3 (+) macrophage cells per mm2 was less in Fgfr1ind-/- mice 
compared with controls in acute and chronic EAE (C and F). Bar: 200 µm, 20 µm 
(insert). n = 3, data are presented as mean ± SEM.  
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4.2.5 Altered pattern of cytokines expression in Fgfr1ind-/- mice spinal cord  
To characterize the underlying molecular mechanisms of cellular activation, 
proinflammatory cytokine mRNA was analyzed in the spinal cord in the acute and 
chronic phase (Figure 29 and 30). In the acute phase Fgfr1ind-/- mice showed 
decreased expression of TNF-α (P < 0.001), IL-1β (P ≤ 0.05) and IL-6 (P < 0.001) 
compared with controls (Figure 29 A, B, C respectively). Expression of inducible NOS 
(iNOS) and IL-12, however, was not changed in Fgfr1ind-/- mice (Figure 30 A and B). 
In the chronic phase no differences in proinflammatory cytokine expression for TNF-
α, IL-1β, IL-6 (Figure 29 D, E and F respectively), iNOS and IL-12 (Figure 30 C and 
D) were observed. 
 
4.2.6 Altered pattern of cytokine expression in Fgfr1ind-/- mice spleen 
To analyze whether relation with the reduced clinical score of Fgfr1ind-/- mice and 
peripheral immune response, we measured proinflammatory cytokine levels in the 
spleen. Spleen from Fgfr1ind-/- and controls of acute and chronic EAE mice were used 
for RNA isolation and DNA were reverse transcribed. The proinflammatory cytokines 
IL-1β, IL-6, IL-12, TNF-α and iNOS expression were measured (Figure 31 and 32).  
 
Proinflammatory cytokine TNF-α which mediate demyelination was significantly 
reduced in spleen of Fgfr1ind-/- on day 22 p.i. (P = 0.0121) and 62 p.i. (P = 0.0475) 
(Figure 31 A and D). In addition, reduced expression of IL-1β in spleen of Fgfr1ind-/- 
mice in acute and chronic phase was observed but not statistically significant (Figure 
31 B and E). IL-6 level was increased in Fgfr1ind-/- spleen in both time points but not 
significant (Figure 31 C and F). IL-12 and iNOS expression were not altered in control 
and Fgfr1ind-/- spleen (Figure 32). 
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Figure 29 Gene expression of proinflammatory cytokine levels in the spinal 
cord of controls and Fgfr1ind-/- mice. Findings at the acute phase (A, B, C) and the 
chronic phase (D, E, F) are shown. At the acute phase decreased mRNA expression 
of TNF-α, IL-1β and IL-6 was observed in Fgfr1ind-/- mice compared with controls. In 
chronic phase the cytokines TNF-α, IL-1β, IL-6 were not different between Fgfr1ind-/- 
mice and controls. n = 9 (acute phase) and n = 6 (chronic phase), data are presented 
as mean ± SEM. 
 
Acute EAE Spinal cord Chronic EAE Spinal cord 
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Figure 30 Gene expression of proinflammatory cytokine levels in the spinal 
cord of controls and Fgfr1ind-/- mice. Findings at the acute phase (A, B) and the 
chronic phase (C, D) are shown. No differences in mRNA expression were seen for 
IL-12 and iNOS. At the chronic phase the cytokines IL-12, iNOS were not different 
between Fgfr1ind-/- mice and controls. n = 9 (acute phase) and n = 6, data are 
presented as mean ± SEM. 
 
 
 
 
 
 
 
 
 
 
Acute EAE Spinal cord Chronic EAE Spinal cord 
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Figure 31 Relative mRNA expression level of proinflammatory cytokines in 
acute (A-E) and chronic (F-J) EAE spleen of control and Fgfr1ind-/- mice. There 
were no significant changes in the expression of proinflammatory cytokines IL-1β (A 
and F), IL-6 (B and G), IL-12 (C and H), inducible NOS (D and I) in spleen of both 
group in acute and chronic EAE. n = 9 (acute phase) and n = 6, data are presented 
as mean ± SEM. 
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Figure 32 Relative mRNA expression level of proinflammatory cytokines in 
acute (A-E) and chronic (F-J) EAE spleen of control and Fgfr1ind-/- mice. There 
were no significant changes in the expression of proinflammatory cytokines iNOS (A 
and C) and IL-12 (B and D) in spleen of both group in acute and chronic EAE. n = 9 
(acute phase) and n = 6, data are presented as mean ± SEM. 
 
 
4.2.7 Chemokine and its receptor expression in Fgfr1ind-/- mice spinal cord 
In addition, to define further molecular mechanisms of cellular activation, the 
expression of the chemokine CX3CL1 and its receptor CX3CR1 in the spinal cord 
were studied in the acute and chronic phase (Figure 33). In the acute phase no effect 
of Fgfr1 deletion on mRNA expression of CX3CL1 or CXC3R1 was seen (Figure 33 A 
and B). In the chronic phase CX3CL1 (P ≤ 0.05) and CX3CR1 (P ≤ 0.05) mRNA was 
decreased compared with controls (Figure 33 C and D).  
 
Acute EAE Spleen Chronic EAE Spleen 
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Figure 33 Gene expression of the chemokine CX3CL1 and the receptor CX3CR1 
in the spinal cord of controls and Fgfr1ind-/- mice. Findings at the acute phase (A, 
B) and the chronic phase (C, D) are presented. At the acute phase no differences 
between Fgfr1ind-/- mice compared with controls were seen. At the chronic phase 
CX3CL1 and CX3CR1 were reduced in Fgfr1ind-/- mice. n = 9 (acute phase) and n = 
6, data are presented as mean ± SEM. 
 
 
4.2.8 Increased ERK and AKT phosphorylation in chronic EAE Fgfr1ind-/- mice 
spinal cord  
Spinal cord lysate from chronic EAE mice were analyzed by western blot to 
investigate the downstream signalling of Fgfr1 pathway. Fgfr1ind-/- mice spinal cord 
showed increased expression of ERK (P = 0.017) and AKT (P = 0.027) 
phosphorylation during chronic EAE (Figure 34 B) and there were no regulation of 
ERK (P = 0.246) or AKT (P = 0.327) phosphorylation in acute phase (Figure 34 A).  
Acute EAE Spinal cord Chronic EAE Spinal cord 
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Figure 34 ERK and AKT phosphorylation in chronic EAE mice spinal cord. 
Increased phosphorylation of ERK and AKT was seen in chronic EAE spinal cord (B). 
There was no regulation of ERK and AKT phosphorylation in acute EAE spinal cord 
(A). GAPDH act as the internal loading control. P values of * P < 0.05, **P < 0.005, 
***P < 0.001 were considered as significant. Values are expressed as mean ± 
standard error of mean. n.s. = not significant.  
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4.2.9 Deletion of Fgfr1 causes changes in BDNF and TrkB receptor expression  
To investigate whether demyelination and axonal damage in the spinal cord was 
accompanied by changes in BDNF synthesis, the effect of oligodendroglial ablation 
of Fgfr1 on the neurotrophin BDNF and its receptor TrkB was studied on mRNA and 
protein levels in the acute (Figure 35) and chronic phase (Figure 36). In the acute 
phase BDNF (Figure 35 B) and TrkB receptor protein (Figure 35 D and E) expression 
was similar between Fgfr1ind-/- mice and controls. In the chronic phase BDNF protein 
(P ≤ 0.05) (Figure 36 B and E) and mRNA expression (P ≤ 0.05) (Figure 36 A) was 
increased in Fgfr1ind-/- mice when compared with controls. Also, in chronic phase 
TrkB receptor protein was increased in Fgfr1ind-/- mice (P < 0.01) (Figure 36 D and E). 
 
4.2.10 Deletion of Fgfr1 in oligodendrocytes mediates the milder disease 
course of chronic EAE through upregulation of PLP 
To analyze the corresponding effect of Fgfr1 deletion in oligodendrocytes on myelin 
related protein expression in EAE, we studied the expression of PLP and MBP 
(Figure 37, 38 and 39). PLP expression is not regulated in Fgfr1ind-/- compared to 
control in acute phase of the disease (P = 0.678) (Figure 37 A and C). Whereas PLP 
expression in Fgfr1ind-/- were upregulated in MOG induced chronic EAE spinal cord 
(day 62 p.i, P = 0.0209, Figure 38 A and C). Myelin basic protein expression was not 
influenced by Fgfr1 deletion in oligodendrocytes in acute (Figure 37 B and D) and 
chronic EAE spinal cord in protein (Figure 38 B and D) and tissue level (Figure 39). 
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Figure 35 Gene expressions and protein quantification of brain-derived 
neurotrophic factor (BDNF) and the TrkB receptor in spinal cord lysates of 
acute EAE controls and Fgfr1ind-/- mice. At the acute phase no effect of Fgfr1 
deletion on BDNF mRNA (A) or protein expression (B) and no effect on TrkB receptor 
mRNA (C) or protein expression (D) were seen. Representative western blot images 
were shown (E). n = 6 (mRNA) and n = 3 (protein), data are presented as mean ± 
SEM. 
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Figure 36 Gene expressions and protein quantification of brain-derived 
neurotrophic factor (BDNF) and the TrkB receptor in spinal cord lysates of 
chronic EAE controls and Fgfr1ind-/- mice. At the chronic phase increased BDNF 
mRNA (A) and protein expression (B) were found in Fgfr1ind-/- mice. TrkB receptor 
protein expression was upregulated in Fgfr1ind-/- mice (D). Representative western 
blots for BDNF and TrkB receptor are shown (E). n = 6 (mRNA) and n = 3 (protein), 
data are presented as mean ± SEM. 
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Figure 37 Effect of oligodendrocyte specific Fgfr1 ablation in the expression of 
proteo lipid protein and myelin basic protein in spinal cord of C57Bl/6J in acute 
phase of MOG EAE. MOG induced EAE was achieved in 10-12 weeks old female 
control and Fgfr1 conditional knockout (specific to oligodendrocytes) mice. Spinal 
cords were removed from acute EAE mice and the spinal cord lysates were analyzed 
for myelin proteins PLP and MBP. In acute EAE protein expression of PLP (A), MBP 
(B) was not altered by Fgfr1 deletion in oligodendrocyte lineage. Representative blots 
were shown (C and D). n.s. = not significant. 
 
 
Figure 38 Effect of oligodendrocyte specific Fgfr1 ablation in the expression of 
proteo lipid protein and myelin basic protein in spinal cord of C57Bl/6J in 
chronic phase of MOG EAE. Proteolipid protein expression was significantly 
upregulated in oligodendrocyte specific Fgfr1 conditional knockout mice spinal cord in 
chronic EAE (A). MBP protein expression was not altered in Fgfr1ind-/- mice spinal 
cord in chronic EAE (B). n.s. = not significant. 
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Figure 39 Myelin basic protein expression in chronic EAE control and Fgfr1ind-/- 
mice spinal cord. Immunohistochemistry analysis of MBP level in spinal cord tissue 
shows no significant differences. Two respective magnifications were shown. 
 
 
4.2.11 Ablation of Fgfr1 affects remyelination inhibitor expression   
To analyze the expression of Fgfr1 in spinal cord of control and Fgfr1ind-/- mice in 
acute and chronic phase of EAE, mRNA expression was analyzed by real time PCR 
(Figure 40). Reduced expression of Fgfr1 mRNA level was seen in acute (P = 0.013; 
Figure 40 A) and chronic (P = 0.017; Figure 40 B) EAE spinal cord of Fgfr1ind-/-.  
To study whether differences in myelin damage in the spinal cord were accompanied 
by changes in inhibition of remyelination, the effect of Fgfr1 on remyelination 
inhibitors such as Lingo-1, FGF2, TGFβ and SEMA3A were studied on mRNA level 
(Figure 41).  In the acute phase no differences for Lingo-1 (Figure 41 A), FGF2 
(Figure 41 G), TGFβ (Figure 41 E) and SEMA3A (Figure 41 C) expression were seen 
between Fgfr1ind-/- mice and controls. In the chronic phase mRNA expression of 
Lingo-1 (Figure 41 B) was decreased in Fgfr1ind-/- mice (P ≤ 0.05), a trend towards 
reduced mRNA expression of FGF2 (Figure 41 H) was seen in Fgfr1ind-/- mice (P = 
0.071). No differences were found for TGFβ and SEMA3A (Figure 41 F and D). 
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Figure 40 Fgfr1 mRNA expression in spinal cord of control and Fgfr1ind-/- mice 
in acute and chronic EAE. Reduced level of Fgfr1 expression was seen in mRNA 
level in acute (A) and chronic (B) EAE spinal cord of Fgfr1ind-/- mice. 
 
4.2.12 Deletion of Fgfr1 does not affect oligodendrocyte lineage cells 
In mouse CNS, olig2 (Kitada und Rowitsch 2006) and nogo-A (Kuhlmann et al. 2007) 
is expressed by oligodendrocyte lineage cells. To answer the question whether 
deletion of oligodendroglial Fgfr1 affects oligodendrocyte lineage cells in EAE the 
number of olig2 (+) and nogoA (+) oligodendrocytes was studied in spinal cord white 
matter lesions in the acute (Figure 42) and chronic phase (Figure 43). There was no 
effect of Fgfr1 deletion on the number of these cells at both time points. A trend 
towards an increased number of nogoA (+) oligodendrocytes in Fgfr1ind-/- mice was 
found both in the acute phase (P = 0.124) and the chronic phase (P = 0.118) (Table 
7; Figure 42 and 43 respectively). 
 
Table 7 Oligodendrocyte lineage cell population in EAE spinal cord. 
Oligodendrocyte 
lineage 
Acute EAE Chronic EAE 
control Fgfr1ind-/- P- value control Fgfr1ind-/- P- value 
olig2 (+) cells 395 ± 91 530 ± 23 
P = 
0.229 
491 ± 
105 
480 ± 39 
P = 
0.927 
nogoA (+) cells 386 ± 72 530 ± 16 
P = 
0.124 
394 ± 80 528 ± 24 
P = 
0.188 
Semiquantitative analysis of oligodendrocyte lineage cell population were shown. 
There were no differences in the number of olig2 and nogoA positive cells in the 
spinal cord of control and Fgfr1ind-/- mice during acute and chronic phase of EAE. 
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Figure 41 Gene expressions of the remyelination inhibitors Lingo-1, SEMA3A, 
TGFβ and FGF2 in the spinal cord of controls and Fgfr1ind-/- mice. Findings at the 
acute phase (A, C, E, G) and the chronic phase (B, D, F, H) are shown. At the acute 
phase Lingo-1, SEMA3A, TGFβ and FGF2 expression was not different between 
Fgfr1ind-/- mice and controls. In the chronic phase both Lingo-1 (B) was reduced in 
Fgfr1ind-/- mice, furthermore a trend towards a reduced expression of FGF2 was seen 
(H). n = 6, data are presented as mean ± SEM. 
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Figure 42 Oligodendrocyte lineage cell populations in control and Fgfr1ind-/- 
mice spinal cord in acute EAE. Olig2 and nogoA positive oligodendrocyte lineage 
cell populations in controls and Fgfr1ind-/- mice spinal cord. There were no differences 
in the population of olig2 (A, B and C) and nogo A (D, E and F) positive cells in 
Fgfr1ind-/- mice spinal cord. n = 3 mice, data are presented as mean ± SEM. 
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Figure 43 Olig2 (+) and nogoA (+) oligodendrocytes in spinal cord sections in 
chronic EAE controls and Fgfr1ind-/- mice. Representative images of spinal cord 
sections at the chronic phase are shown. There were no differences in the number of 
olig2 (+) oligodendrocytes (A, B and C). A trend towards an increased number of 
nogoA (+) oligodendrocytes in Fgfr1ind-/- mice was seen at the chronic phase (D, E 
and F). n = 3 mice, data are presented as mean ± SEM. 
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4.3 Milder EAE score in IFN β-1a treated Fgfr1ind-/- mice 
 
 
             
Figure 44 Effects of Interferon β-1a treatment in chronic EAE. Chronic EAE was 
induced in control and Fgfr1ind-/- mice and IFN β-1a was treated from day 0 till day 7 
post immunization. EAE score were monitored till day 62. A) IFN β-1a treated 
Fgfr1ind-/- mice showed milder EAE disease course (70 % milder). B) Cumulative EAE 
score of control, Fgfr1ind-/- and Fgfr1ind-/- mice treated with IFN β-1a. Significant milder 
score was seen in Fgfr1ind-/- and IFN β-1a treated Fgfr1ind-/- mice.               
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Mice with oligodendroglial Fgfr1 deletion (Fgfr1ind-/-) were analyzed for their 
susceptibility to MOG35-55 peptide EAE induction (Figure 8). To investigate IFN β-1a 
treatment effect in Fgfr1ind-/- mice during chronic EAE, EAE was induced in eight to 
twelve-week-old female Fgfr1ind-/- mice and compared with age- and sex-matched 
controls. Following IFN β-1a treatment from day 0 till day 7 p.i. mice were assessed 
for clinical symptoms (Figure 44 A). The onset of clinical symptoms was on day 11 
p.i. in control and Fgfr1ind-/- mice treated with IFN β-1a. The mean maximum disease 
score was 2.7 in control and 1.5 in IFN β-1a treated Fgfr1ind-/- mice (P ≤ 0.001). IFN 
β-1a treated Fgfr1ind-/- mice showed a milder disease course than controls (P ≤ 
0.001). In this disease phase, Fgfr1ind-/- mice presented with a mild paraparesis 
whereas controls still suffered from a severe paraparesis. Also, the cumulative EAE 
score was higher in controls (P ≤ 0.001; Figure 44 B). Disease incidence was 100%. 
No effect of gene deletion on mortality was observed. There were no differences in 
body weight between Fgfr1ind-/- and control mice.  
          
4.4 In vitro experiments 
 
4.4.1 The effects of Fgfr1 inhibition and IFN β-1a in oli-neu oligodendrocytes 
PD166866 is a potent Fgfr1 inhibitor which is used to analyze in vitro role of Fgfr1 in 
oligodendrocyte cells oli-neu. Fgfr1 inhibitor PD166866 showed significant reduced 
proliferation in oli-neu cells. There was no proliferation effect of IFN β-1b treatment in 
oli-neu cells. Combined treatment of IFN β-1b and PD166866 reduce the proliferation 
effect of oli-neu cells (Figure 45).  There was no effect of Fgfr1 inhibition and IFN β-
1b on cytotoxicity in oli-neu cells (Figure 46). ERK1/2 phosphorylation was decreased 
by Fgfr1 inhibition in oli-neu cells and there was no effect of IFN β-1b on ERK1/2 
phosphorylation (Figure 47). Combination of Fgfr1 inhibition and IFN β-1b treatment 
does not reduce the ERK1/2 phosphorylation as in either Fgfr1 inhibition or IFN β-1b 
treatment alone (Figure 47). IFN β-1b enhances STAT1 phosphorylation and Fgfr1 
does not influence STAT1 phosphorylation (Figure 47).  
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Figure 45 Proliferation effects of Fgfr1 inhibition and IFN β-1b treatment in 
oligodendrocyte oli-neu cell line by WST assay. Oli-neu cells were incubated with 
PD166866 to inhibit Fgfr1 and IFN β-1b was treated and proliferation was estimated. 
Fgfr1 inhibition decrease the proliferation and IFN β-1b treatment does not affect the 
proliferation. *** represent < 0.001. 
 
  
Figure 46 Cytotoxicity effects of Fgfr1 inhibition and IFN β-1b treatment in 
oligodendrocyte oli-neu cell line by LDH assay. Oli-neu cells were incubated with 
PD166866 to inhibit Fgfr1 and IFN β-1b was treated and cytotoxicity was estimated. 
There is no effect of Fgfr1 inhibition and IFN β-1b on cytotoxicity of oli-neu cells. n.s = 
not significant. 
 
                
Figure 47 Expression of ERK1/2 and STAT1 phosphorylation upon Fgfr1 
inhibition and IFN β-1b on oli-neu cell line. Upon Fgfr1 inhibition and IFN β-1b 
treatment, ERK1/2 and STAT1 phosphorylation were checked by western blotting. 
ERK phosphorylation decreases after Fgfr1 inhibition and no effect in IFN β-1b 
treatment. pSTAT1 is upregulated after IFN β-1b treatment in oli-neu cells.  
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5 DISCUSSION 
 
Fibroblast growth factors and its receptors (FGF/FGFR) play a major role in 
embryogenesis and development of organs, and contribute to the development of 
CNS. In the present study the in vivo function of FGF receptor 1 was characterized 
using an oligodendrocyte-specific genetic approach. We have seen milder disease 
course in Fgfr1ind-/- mice in MOG35-55-induced EAE which is contrasting to our 
hypothesis. Fgfr1ind-/- mice showed a milder the disease course. The pathological 
analysis showed decreased lymphocyte and macrophage/microglia infiltration, and 
myelin and axon degeneration in Fgfr1ind-/- mice. In addition, in acute EAE down 
regulation of proinflammatory cytokines such as TNF-α, IL-1β and IL-6 and in chronic 
EAE down regulation of the CX3CL1/CX3CR1 was seen in Fgfr1ind-/- mice. 
Furthermore, increased expression of TrkB/BDNF and decreased expression of 
Lingo-1 was found in Fgfr1ind-/- mice. 
 
5.1 Oligodendrocyte specific Fgfr1 knock out in C57Bl/6J mice 
 
5.1.1 Fgfr1 deletion in oligodendrocytes does not result in phenotypic changes 
 
FGF/Fgfr1 signalling has been involved in numerous cellular processes, including 
proliferation, differentiation and survival (Knights and Cook 2010). It was shown that 
complete or partial loss of Fgfr1 resulted in lethality at embryonic days 7-12.5. Xu et 
al. developed Fgfr1 conditional knockout allele using the Cre-loxP system (Xu et al. 
2002). The Fgfr1 knockout in keratinocytes caused progressive loss of skin 
appendages, cutaneous inflammation (Yang et al. 2010). Moreover, Fgfr1 deficient 
embryos displayed severe growth retardation and died prior to or during gastrulation 
because of intrinsic blocks in mesoderm differentiation, and mice with targeted 
deletion of Fgfr1 in mesenchymal cells leads to the death of mice at birth and mice 
that lack the Frs-binding site on Fgfr1 died during late embryogenesis (Su et al. 
2014). Furthermore, Smith et al. (2014) showed reduced number of perivascular 
positive cortical interneurons in conditional knockout of Fgfr1 in neuron 
(Fgfr1fl/fl;Nestin-Cre+ mice) and astrocytes (Fgfr1fl/fl;hGFAP-Cre+ mice) under nestin and 
GFAP promoters respectively. Recently, Zhou et al. (2012) showed the conditional 
deletion of Fgfr1 in oligodendrocyte lineage cells by Tamoxifen inducible Cre 
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mediated system and reduced Fgfr1 expression. Here we used a Tamoxifen 
inducible system of cre mediated Fgfr1 deletion in oligodendrocyte lineage cells in 
C57BL/6J mice line. The principle conclusion that emerges from our results in 
Fgfr1ind-/- mice phenotype is that conditional deletion of Fgfr1 in oligodendrocytes 
under Plp promoter does not show phenotypic changes.  
 
5.1.2 Increased ERK and AKT phosphorylation in Fgfr1ind-/- mice 
Spinal cord and cortex whole lysates of control and Fgfr1ind-/- mice showed no 
differences in the expression of Fgfr1 or Fgfr2, because the conditional knockout 
system allows the deletion of Fgfr1 specifically in oligodendrocyte lineage cells. We 
demonstrated that the loss of Fgfr1 in oligodendrocyte lineage cells resulted in an 
increased phosphorylation of ERK, AKT and TrkB receptors in spinal cord.  Fgfr1 
autophosphorylation internally activates ERK and AKT pathways which lead to 
proliferation, survival and differentiation of oligodendrocyte lineages. Hence, we 
expected that conditional deletion of Fgfr1 in oligodendrocyte lineage will decrease 
the ERK and AKT signalling pathways. However, an increased phosphorylation of 
ERK and AKT was detected in Fgfr1ind-/- mice cortex and spinal cord whole lysates. 
The influence of oligodendrocyte specific Fgfr1 in ERK and AKT expression in whole 
lysates of spinal cord and cortex is not understood well. It has been shown that 
increased AKT expression mediate enhanced myelination in CNS (Flores et al. 
2008). This increase that is observed in Fgfr1ind-/- mice might be due to compensatory 
mechanisms through other growth factor receptors such as Fgfr 3 or 4. Moreover, the 
variation in the response of oligodendrocyte Fgfr1 to whole lysate downstream 
pathways, both within CNS tissues and between CNS tissues, is likely to reflect 
combination of unknown factors, including the response of individual 
oligodendrocytes on site. 
 
The study of the Fgfr1 signalling pathway initiated by conditional knockout system is 
currently an emerging field of investigation. Fgfr signalling permits or promotes olig2 
gene transcription (Easin et al. 2010). Fgfr signalling maintains a basal level of MAPK 
phosphorylation, which is essential for olig2 expression. Mechanisms behind 
oligodendrocyte progenitor cell generation through Fgfr are not well understood. 
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However, Fgfr1 is a tyrosine kinase receptor that initiates a number of well 
characterized signalling pathways such as Shc-Ras-Erk (MAPK/ERK), PI3K/AKT, 
and PLC-γ pathways (Turner and Grose 2010). Some of these pathways have been 
implicated in regulating myelination. The expression of constitutively active AKT in 
oligodendrocyte progenitor cells and oligodendrocytes (via the PLP promoter) 
exerted no influence on oligodendrocyte number, but dramatically increased myelin 
thickness (Flores et al. 2008, Narayanan et al. 2009). ERK1/2 MAPK pathway has 
been shown to be a major contributor leading to the induction of oligodendrocyte 
progenitors in spinal cord. Besides, inhibition of ERK1/2 MAPK by chemical inhibitor 
also inhibits the induction of olig2 cells in cultures of spinal cord in vitro. It is difficult 
to interpret these findings in the aspect of oligodendrocyte specific Fgfr1 in whole 
spinal cord as little is known about the molecular events in oligodendrocyte Fgfr1 in 
altering signalling pathway in whole lysate.  
 
On top of those Furusho et al. (2011) shown that loss of Fgfr1 or Fgfr2 in 
oligodendrocytes does not affect the proliferation or cell death of oligodendrocyte 
progenitor cells. They examined oligodendrocyte proliferation and cell death in 
forebrains of Fgfr1-/- mutants and their littermate controls on E12.5 day. They 
measured the proliferation of oligodendrocyte progenitors in cultures initiated from 
E12.5 day control and Fgfr1 mutant forebrains and showed no differences in the 
number of oligodendrocyte progenitor cells either in vivo or in vitro.  
 
5.1.3 Increased TrkB expression in Fgfrind-/- mice spinal cord 
In our study, Fgfr1ind-/- cortex and spinal cord showed increased expression of TrkB, 
brain stem and cerebellum showed there was no difference in TrkB expression. 
Brain-derived neurotrophic factor (BDNF) belongs to the neurotrophin family of 
growth factors and signals via two distinct classes of receptors: tropomyosin-related 
kinase (Trk) B and p75. In vitro studies have identified that BDNF exerts direct effects 
on oligodendroglia, variously promoting OPC proliferation and differentiation, as well 
as myelination via activation of endogenous TrkB receptors on oligodendroglia (Xiao 
et al. 2010). BDNF/TrkB clearly exerted a positive effect on myelination; however, it 
remained unclear whether this was primarily a neuronal or oligodendroglial-mediated 
effect. Also, BDNF and its receptor TrkB are expressed in macrophages (Artico et al. 
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2008) and play autocrine and paracrine roles in the modulation of regeneration and 
angiogenesis following nerve injury (Kermani and Hempstead 2007). The reason for 
this diversity in response of oligodendrocytes to TrkB in vivo is unclear, but could be 
due to regional differences and heterogeneity of progenitor populations of the cells in 
the specific tissues. Thus the molecular substrates present in the Fgfr1 mediated 
BDNF/TrkB expression remains unknown and several other negative feedback 
mechanisms that may exist to control the adverse effect of oligodendrocyte Fgfr1 
over activation need to be further investigated.  
 
5.2 Oligodendrocyte specific Fgfr1 inhibition reduces chronic EAE  
In our present study the in vivo function of Fgfr1 was characterized using an 
oligodendrocyte-specific genetic approach, which allowed defining the function of this 
receptor in a cell-specific and inducible fashion. Impaired signalling via 
oligodendroglial Fgfr1 resulted in a milder disease course. Recent studies suggest 
that Fgfr1 plays a role in multiple sclerosis and its model EAE. Fgfr1 is up regulated 
in oligodendrocyte precursor cells within active and around chronic multiple sclerosis 
brain lesions (Clemente et al. 2011). In EAE, Fgfr1 is expressed on effector cells 
such as macrophages and activated microglia (Liu et al. 1998). 
 
The key clinical finding of our study is that Fgfr1ind-/- mice showed a milder disease 
course in the chronic phase of EAE. Furthermore, Fgfr1ind-/- mice is presented with a 
delay in onset of symptoms and less maximum disease severity. This pattern of 
milder EAE disease course during chronic phase is particularly interesting. These 
clinical findings are in contrast to those obtained after systemic deletion of its key 
ligand FGF2. FGF2-/- mice are more severely affected in the chronic phase of EAE 
(Rottlaender et al. 2011), a finding, which is supported by data from a FGF2 gene 
therapy study (Ruffini et al. 2001). In addition, intrathecal injection of a HSV 
multigene vector engineered with the human FGF2 gene at day 20 after EAE 
induction also resulted in a milder disease course.  
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5.2.1 Reduced immune cells in Fgfr1ind-/- mice 
In both acute and chronic phases of EAE, impaired signalling via Fgfr1 was 
associated with a decreased number of macrophages/activated microglia and B220 
(+) B cells in the spinal cord. Macrophages are the dominant effector cell population 
in the acute phase of EAE (Gold et al. 2006). Activated macrophages and microglia 
release a number of soluble factors such as nitric oxide (NO), excitotoxines and 
proteases, which cause structural damage in the CNS (Gold et al. 2006). In Fgfr1ind-/- 
mice a significant reduction of CD3 (+) T cells was observed only in the chronic 
phase of EAE. In EAE, myelin specific T cells, which are activated in the periphery 
migrate into the CNS. In the CNS these T cells are reactivated resulting in the 
release of proinflammatory cytokines and chemokines (Fletcher et al. 2010). Data on 
oligodendrocyte-specific Fgfr1 ablation and immune cell infiltration into the CNS are 
not available from the toxic demyelination model (Zhou et al. 2012). In contrast to our 
findings, in FGF2-/- mice the number of macrophages and T cells are increased in 
acute EAE (Rottlaender et al. 2011). B220 (+) cell infiltration is regulated by 
oligodendroglial Fgfr1 in our study. The contradicting findings that we observed in the 
disease course and cellular infiltration between Fgfr1ind-/- and FGF2-/- mice may be 
explained by alternative binding of other ligands to Fgfr1 or activation of other FGFRs 
by FGF2 (Reuss and von Bohlen 2003). Our data indicate that oligodendrocyte Fgfr1 
exerts important and independent effects that directly or indirectly influence immune 
cell infiltration and perhaps more importantly in chronic phase of EAE. 
 
In vitro data suggest that the deleterious effects of Fgfr1 activation by FGF2 on 
differentiated oligodendrocytes are associated with a downregulation of myelin 
proteins (Fortin et al. 2005). Myelin sheaths play an important role in protecting axons 
from degeneration (Irvine and Blakemore 2008). Our findings suggest that impaired 
signalling via oligodendroglial Fgfr1 results in decreased demyelination. 
Oligodendroglial Fgfr1 did not affect the number of oligodendrocyte lineage cells in 
our model. In the model of toxic demyelination reduced Fgfr1 expression is 
associated with increased oligodendrocyte repopulation (Zhou et al. 2012). Fgfr1ind-/- 
mice showed enhanced axonal density in our study, which is in accordance with 
findings in the model of toxic demyelination (Zhou et al. 2012). 
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5.2.2 Decreased cytokines in Fgfr1ind-/- mice  
In the acute phase of EAE, impaired signalling via Fgfr1 was associated with 
decreased secretion of proinflammatory cytokines such as TNF-α, IL1-β and IL-6. 
Microglia produces TNF-α, IL-6 and IL-1β in response to IFN-γ (Rodgers and Miller 
2012). Signalling via Fgfr1 did not change expression levels of these cytokines in the 
chronic phase of EAE. Myelin degeneration and axon remyelination failure in 
oligodendrocytes, which are associated with differentiation dysfunction, are 
pathological hallmarks of MS. It is known that cytokines affect the permeability of the 
blood brain barrier, oligodendrocyte progenitor differentiation, activation of microglia 
and astrocytes to participate in disease progression and remyelination. Several lines 
of evidence indicate that TNF-α is one of the most relevant cytokines involved in the 
pathogenesis of this disease (Bonora et al. 2014). TNF-α is a key mediator of 
inflammation in multiple sclerosis (Caminero et al. 2011, Lock et al. 2002) and EAE 
(Hidaka et al. 2014, Lock et al. 2002).  
 
In our study, Fgfr1ind-/- mice showed less TNF-α compared to control mice which is 
associated by disease recovery of Fgfr1ind-/- mice. TNFα is produced by infiltrating 
immune cells and activated glia (astrocytes and microglia) in multiple sclerosis 
(Caminero et al. 2011, Rodgers and Miller 2012) and EAE (Gold et al. 2006). In vitro 
TNF-α inhibits oligodendrocyte progenitor cell proliferation and differentiation through 
a mitochondria-dependent process (Bonora et al. 2014). The Th1 cytokines, IFN-γ 
and TNF-α, were both higher in MS patients, but only the TNF-α levels were 
statistically significant (Lovett-Racke et al. 2011). TNF-α signalling mediates cell 
death cascades through activating one or more of the three pathways such as 
nuclear factor (NF)κB, MAPK and caspases. TNF-α inhibits oligodendrocyte 
progenitor cell proliferation and differentiation and also induces mature 
oligodendrocyte apoptosis (Rodgers and Miller 2012).  
 
IL-1β promotes pathogenic Th17 differentiation, T cell trafficking, and CNS tissue 
damage. There is also evidence that suggests that IL-1β causes disruption in 
inhibitory connections in the cerebellum during EAE and MS (Rodgers and Miller 
2012). Both IL-6 (Quintana et al. 2009, Steinman 2008) and IL-1β (Prins et al. 2013, 
Rossi et al. 2012) are mediators of inflammatory responses in the white matter and 
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contribute to the development of brain lesions in multiple sclerosis and EAE. It is 
known that IL-1β plays a role in demyelination, breakdown of blood-brain barrier 
(BBB), microglia activation and promotion of IL-17 expression (Inoue and Shinohara 
2013). In our results, Fgfr1ind-/- mice showed increased expression of BDNF and 
reduced IL-1β expression in spinal cord which is in agreement with one alternative 
hypothesis that BDNF primarily reduce IL-1β expression, thereby attenuating 
astrocytosis (Lin et al. 2006) and microgliosis (Basu et al. 2002). 
 
5.2.3 Decreased chemokines in Fgfr1ind-/- mice  
More specifically, we asked how target removal of Fgfr1 in oligodendrocytes affects 
the immune cell infiltration. Chemokine mediated immune cell infiltration through 
Fgfr1 has been reported (Reed et al. 2012). There is evidence for a role of the 
CX3CL1/CX3CR1 pathway in multiple sclerosis and EAE. Molecular signalling 
through fractalkine (CX3CL1), a nociceptive chemokine, via its receptor (CX3CR1) is 
thought to be associated with MS. CX3CR1 is present on astrocytes and 
oligodendrocytes in active and silent multiple sclerosis lesions (Omari et al. 2005). 
Increased expression of serum CX3CL1 is observed in patients with multiple 
sclerosis (Kastenbauer et al. 2003). Data from a genetic study suggest that the 
CX3CR1 I249T280 haplotype may protect from switch to secondary progressive 
multiple sclerosis (Stojkovic et al. 2012). In rats CX3CL1 and CX3CR1 are expressed 
by neurons, astrocytes and microglia (Sunnemark et al. 2005). In the chronic phase 
of EAE we observed that impaired signalling via oligodendroglial Fgfr1 was 
associated with decreased immune cell infiltration through the CX3CL1/CX3CR1 
pathway, Fgfr1 does not seem to affect this pathway in the acute phase. CX3CR1-
deficient mice have been shown to have a more severe disease course, and 
increased IFN-γ expression (Garcia et al. 2013).  
 
Treatment with an anti-CX3CL1 antibody resulted in reduced clinical disease severity 
and less lymphocyte infiltration in acute EAE. In addition, in EAE model of MS, Zhu et 
al. (2013) showed significant increases in mRNA and the protein expression of 
CX3CL1 and CX3CR1 in the dorsal root ganglia (DRG) and spinal cord 12 days after 
EAE induction compared to controls. Furthermore, this increased expression 
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correlated with the peak neurological disability caused by EAE induction. In 
inflammatory state, increased expression of CX3CL1 occurs in neurons and also in 
astrocytes in the dorsal horn of the spinal cord. CX3CL1 is usually expressed in the 
normal rodent CNS tissue by different neuronal cell subtypes (Harrison et al. 1998). 
In addition, it is also expressed in monocytes, natural killer (NK) cells, and smooth 
muscle cells (Lindea et al. 2005). The CX3CL1 receptor, CX3CR1, is constitutively 
expressed in microglia of the brain and spinal cord and is significantly increased as a 
result of microglial activation (Harrison et al. 2005).  
 
Following inflammation, injured neurons release adenosine triphosphate (ATP), 
which binds to the P2X7 receptor on microglia that subsequently causes the release 
of the protease Cathepsin S (Coddou et al. 2011). CX3CL1 is bound to the neuronal 
membrane and is cleaved by the Cathepsin S (Clark et al. 2010). Soluble CX3CL1 
binds to the CX3CR1 on microglia resulting in the increased synthesis and release of 
pronociceptive mediators such as IL-6 and nitric oxide. TNF-α also involved in the 
post transcriptional regulation of CX3CL1 and TNF-α is a critical upstream factor that 
regulates CX3CL1 production (Isozaki et al. 2010). Up-regulation of TNF- α in spinal 
cord may be a critical early step in regard to the regulation of MS induction via 
CX3CL1/CX3CR1 signalling pathway. However, further studies are also required to 
study the effect of TNF-α on CX3CL1 expression in spinal cord oligodendrocytes. 
 
Our findings suggest that the CX3CL1/CX3CR1 pathway is controlled by 
oligodendroglial Fgfr1 in the chronic phase of EAE. The cell migration mechanism 
was explained with IL-1β and IL-18, which are processed by the inflammasome and 
up-regulate expression of chemokines and their receptors in both in T cells and 
antigen presenting cells (Inoue and Shinohara 2013). It is our belief that the 
oligodendrocyte specific Fgfr1 and CX3CL1/CX3CR1 signalling crosstalk in spinal 
cord may be involved in the underlying pathology in EAE. 
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5.2.4 Increased neuronal growth factors in Fgfr1ind-/- mice  
BDNF is a neurotrophic factor involved in neuronal survival and differentiation as well 
as axonal growth (Chao 2003). Oligodendrocytes produce BDNF that promote the 
survival of neurons, advancing oligodendrocyte differentiation and myelination, 
especially during CNS myelin lesion and repair (Bankston et al. 2013). However, how 
BDNF expression is regulated in oligodendrocyte is much less understood. It has 
been proven that BDNF is a suppressing factor for macrophage migration and 
infiltration and may play a detrimental role after spinal cord injury (Wong et al. 2010) 
and intracerebroventricular administration of BDNF has been reported to significantly 
reduce blood brain barrier breakdown. In multiple sclerosis immune cells are a major 
source of BDNF (Kerschensteiner et al. 1999). More BDNF (+) cells are found in 
active demyelinating lesions compared with inactive lesions (Stadelmann et al. 2002). 
Furthermore, neurons around active lesions and reactive astrocytes within lesions 
express high levels of its high affinity receptor gp145trkB (Stadelmann et al. 2002).  
 
In EAE (Lee et al. 2012, Linker et al. 2010) and other lesion models (Markus et al. 
2002) BDNF is expressed by activated immune cells and it is also associated with 
axonal protection (Linker et al. 2010). In the present study we observed increased 
BDNF or TrkB levels in the chronic phase of EAE in Fgfr1ind-/- mice suggesting that 
expression of these molecules is regulated by oligodendroglial Fgfr1. In post-mortem 
tissue from patients different inhibitors of oligodendrocyte precursor cell 
differentiation have been detected (Kotter et al. 2011). Ultimately CNS myelination is 
orchestrated by an unknown number of extracellular factors and the removal of the 
Fgfr1 in oligodendrocytes may be sufficient to enhance the intracellular signalling 
cascades that regulate the remyelination. Taken together, these results suggest that 
inhibition of oligodendrocyte Fgfr1 can promote both the expression of BDNF and its 
receptor TrkB in chronic phase of EAE, hence promoting an enhanced recovery of 
Fgfr1ind-/- mice in chronic EAE.  
 
TrkB activation leads to an enhanced PI3K/AKT and ERK1/2 signalling in the retinal 
ganglion cells (RGCs), ERK1/2 in particular appears to be responsible for promoting 
the survival of RGCs (Gupta et al. 2013). Blocking Lingo-1 in retina enhances AKT 
signalling in increased intra-ocular pressure animal models and thus plays a 
neuroprotective role (Gupta et al. 2013). 
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5.2.5 Decreased myelin inhibitors in Fgfr1ind-/- mice  
A molecule correlating with the extent of oligodendrocyte maturation and myelination 
is Lingo-1, a transmembrane protein with leucine rich repeats and an immunoglobulin 
domain expressed in neurons and oligodendrocytes. The nogo receptor-interacting 
protein (Lingo-1) is a key inhibitor of oligodendrocyte precursor cell differentiation and 
myelination in vitro (Mi et al. 2005) and in vivo (Mi et al. 2007). Deletion of Lingo-1 
causes a less severe EAE disease course, improved axonal integrity, promoted axon 
remyelination (Mi et al. 2007), increased myelination, whereas its overexpression 
inhibits myelin formation (Bradl and Lassmann 2010). An anti-Lingo-1 antagonist 
applied before and after onset of symptoms results in less disease activity in acute 
EAE (Mi et al. 2007). In our study impaired signalling via oligodendroglial Fgfr1 was 
associated with downregulated Lingo-1 expression in the chronic phase of EAE 
suggesting that this inhibitor is controlled by oligodendroglial Fgfr1 as well. 
Collectively, these data suggest a mechanism wherein FGF, signalling through 
oligodendrocyte-expressed Fgfr1, could be a key factor influencing inflammation 
through mediating chemokines and neuronal growth factors and receptors. In 
addition, data showed that inhibition of Lingo-1 activity in vitro and in vivo promotes 
outgrowth of oligodendrocyte processes and leads to highly developed myelinated 
axons (Zhou et al. 2012a). 
 
Our finding that signalling via oligodendroglial Fgfr1 modulates clinical disease 
activity and inflammation gives the opportunity for a targeted molecular therapy. 
Selective and multikinase FGFR inhibitors are currently being tested in patients with 
genetically selected tumors with promising efficacy in some of these trials 
(Dienstmann et al. 2014). Tyrosine kinase inhibitors are active against kinases such 
as VEGFR or PDGFR. Luzitanib, a VEGFR/FGFR inhibitor has been applied 
successfully in FGFR1-amplified breast tumors (Dienstmann et al. 2014). In addition, 
monoclonal antibodies such as FP-1039 binding to the extracellular domain of 
FGFRs are used in clinical testings (Dienstmann et al. 2014). Signalling via 
oligodendroglial Fgfr1 also modulates Lingo-1 expression suggesting that Lingo-1 
inhibition could be a promising approach to further decrease the effects of the 
receptor. A Lingo-1 antagonist has been used successfully to promote remyelination 
in EAE (Mi et al. 2007) and inhibition of Lingo-1 is has been tested in a Phase I 
clinical multiple sclerosis trial (NCT01244139). 
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Lingo-1 is the co-receptor of Nogo-66 receptor (NgR1) and lack of Lingo-1 will 
significantly decrease the activity of the NgR1 signalling pathway. Binding of Lingo-1 
with NgR1 can activate the NgR1 signalling pathway, leading to inhibition of 
oligodendrocyte differentiation and myelination in the central nervous system (Zhou 
et al. 2012a). Lingo-1 has also been found to bind with epidermal growth factor 
receptor (EGFR) and induce down regulation of the activity of EGFR–PI3K–AKT 
signalling (Zhou et al. 2012a), whereas the interaction of Lingo-1 with FGFR1 is not 
known. We provided evidence for Lingo-1 downregulation and increased AKT 
phosphorylation in Fgfr1ind-/- mice.  
 
Our data clearly point to a key role for Fgfr1 expressed by oligodendrocytes in 
MOG35-55 induced EAE. Importantly, our strategy to selectively delete Fgfr1 from 
oligodendrocytes is the first to unequivocally identify a clear role for Fgfr1 in 
mediating CNS repair in EAE. Other studies have implicated Fgfr1 in CNS 
myelination; for example, targeted deletion of Fgfr1 in oligodendrocyte lineage cells 
by the PLP promoter showed significantly enhanced axonal density and number of 
oligodendrocytes in cuprizone mediated toxic demyelination model (Zhou et al. 
2012). 
 
5.3 IFN β-1a treatment causes a milder disease course in Fgfr1ind-/- mice 
Interferon β-1a treated Fgfr1ind-/- mice showed delayed onset of disease and milder 
disease course of EAE. Type 1-interferons (IFN-1) such as IFN-α and IFN-β, are 
involved in various aspects of immune responses. IFN-β has been used for more 
than 15 years as a first-line treatment for MS, and also markedly attenuates EAE 
development. The mechanisms of action of IFN-β involves multiple immunoregulatory 
functions, including blocking the trafficking of lymphocytes to the CNS (Floris et al. 
2002), reducing expression of major histocompatibility class II molecules (Jiang et al. 
1995), attenuating T cell proliferation and altering the cytokine milieu from pro-
inflammatory to anti-inflammatory (Ramgolam et al. 2009). The combination of Fgfr1 
knockdown and selective preventive treatment with IFN β-1a in our EAE model 
confirms that Fgfr1 is an attractive target for therapeutic intervention.  
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In vitro, PD166866, a potent Fgfr1 inhibitor does not show enhanced oli-neu 
oligodendrocyte cell proliferation. Fgfr1 regulates proliferation and differentiation 
through ERK and AKT pathways. Inhibition of Fgfr1 in vitro down regulates oli-neu 
cell proliferation. The reason for this diversity in response of oligodendrocytes to 
Fgfr1 in vivo is the cross talk and heterogeneity of progenitor populations of the cells 
in the specific tissues. Although we do not fully understand the mechanism of action 
of the Fgfr1 inhibition and IFN β-1b combination in oli-neu cells, future studies are 
needed to clarify the mechanisms behind the regulation. Considering that FGFR 
inhibitors are used in cancer trials, the oligodendroglial Fgfr1 pathway may provide a 
new target for therapy in multiple sclerosis.  
 
FGFR pathway plays a distinct and major role in cancer as it directly promotes the 
endothelial cell proliferation and tumor neoangiogenesis and having complementary 
and synergistic effects with the vascular endothelial cell growth factor (VEGF) 
signalling (Dienstmann et al. 2014). Recent knock down and selective 
pharmacological inhibition of FGFR studies promote FGFR as a target for cancer 
treatment. Different FGFR pathway aberrations have been identified in cancer. (i) 
receptor overexpression by gene amplification or post-transcriptional regulation; (ii) 
mutated FGFR produces constitutively active or exhibit reduced dependence on 
ligand binding for activation; (iii) constitutive FGFR kinase activity with the expression 
of FGFR-fusion protein; (iv) alternative splicing of FGFR and isoform switching, which 
substantially alters ligand specificity increasing the range of FGFs that can stimulate 
tumor cells; and (v) up-regulation of FGF expression in cancer or stromal cells and 
the enhanced release of FGFs from the extracellular matrix, resulting in paracrine/ 
autocrine activation of the pathway (Dienstmann et al. 2014). 
 
In conclusion, the present study provides first evidence that inhibition of Fgfr1 in 
oligodendrocytes enhanced recovery of chronic EAE through controlling of immune 
cell infiltration. This effect may be caused by a reduction of activated immune cells 
and decreased cytokine and chemokine levels. Therefore, oligodendroglial Fgfr1 may 
represent an interesting therapeutic target for MS. The detailed molecular 
mechanism(s) will have to be explored in the future.  
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6 SUMMARY 
 
Fibroblast growth factor and receptors play an important role in various cellular 
processes in CNS. Role of Fgfr1 in Multiple sclerosis and EAE is not understood, a 
recent study on toxic demyelination oligodendroglial Fgfr1 knockout mice showed 
increased axonal density and remyelination. 
 
The current study focuses on the oligodendroglial Fgfr1 in EAE, an animal model for 
Multiple sclerosis. There were no phenotypic differences in the Fgfr1ind-/- mice. 
Impaired signalling via oligodendroglial Fgfr1 had a beneficial effect on MOG35-55-
induced EAE. Ablation of oligodendroglial Fgfr1 reduced the disease course, cellular 
inflammation, demyelination and increased axonal density. Cellular inflammation was 
regulated by the proinflammatory cytokines TNF-α, IL-1β and IL-6, and the 
chemokine CX3CL1-CX3CR1 pathway in our model. Increased BDNF and TrkB 
receptor expression was seen in Fgfr1ind-/- mice in our model associated with disease 
recovery. Myelin inhibitor Lingo-1 expression was less in Fgfr1ind-/- mice in chronic 
EAE. IFN β-1a prevention treatment caused the milder EAE disease course in 
Fgfr1ind-/- mice. Ablation of Fgfr1 in oligodendrocytes showed an increased 
expression of ERK and AKT phosphorylation and TrkB and BDNF expression in the 
spinal cord. Considering that FGFR inhibitors are used in cancer trials, the 
oligodendroglial Fgfr1 pathway may provide a new target for therapy in multiple 
sclerosis.   
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ZUSAMMENFASSUNG 
  
Der Fibroblasten-Wachstumsfaktor und seine Rezeptoren spielen eine wichtige Rolle 
in verschiedenen Zellprozessen im ZNS. Welche Rolle Fgfr1 bei MS (Multiple 
Sklerose) und EAE (Experimentelle autoimmune Enzephalomyelitis) spielt, ist 
unbekannt. Eine Studie zur Funktion des  Oligodendrozyten-spezifischen Fgfr1 in 
dem Cuprizone-Modell ergab, dass das Fehlen von FGFR1 zu einem axonalen 
Dichteverlust führt. 
 
Die vorliegende Studie richtet ihren Fokus auf das Oligodendrozyten-spezifische 
Fgfr1 bei EAE, einem Tiermodell für MS. Es gab keine Unterschiede im Phänotyp 
von Fgfr1ind-/--Mäusen. Der Signalweg, der  durch oligodendrozytäres Fgfr1 vermittelt 
wird, führt zu einem milderen Krankheitsverlauf, geringerer zellulärer Inflammation 
und weniger Degeneration von Myelinscheiden und Axonen. Die zelluläre 
Inflammation wird durch die proinflammatorischen Zytokine TNF-α, IL-1β und IL-6 
und den Pathway der Chemokine CX3CL1-CX3CR1 reguliert. Präventive 
Behandlung mit IFN β-1a mildert den Krankheitsverlauf von EAE in Fgfr1ind-/- Mäusen 
ab. Die Entfernung von Fgfr1 in Oligodendrozyten führt zu einer vermehrten 
Expression von ERK und AKT-Phosphorylierung sowie TrkB- und BDNF-Expression. 
Unter der Annahme, dass Fgfr1-Inhibitoren in der Krebstherapie eingesetzt werden, 
könnte der oligodendrozytäre Fgfr1-Signalweg ein Ziel für eine Therapie der 
Multiplen Sklerose darstellen. 
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